

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/046145 A2

(51) International Patent Classification: **C12N**

(21) International Application Number: PCT/US02/38075

(22) International Filing Date:
27 November 2002 (27.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/995,263 27 November 2001 (27.11.2001) US

(71) Applicant (for all designated States except US): **THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS** [US/US]; 352 Administration Building, 506 South Wright Street, Urbana, IL 61801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ONYUKSEL, Hayat** [US/US]; 4146 Claussen Avenue, Western Springs, IL 60558 (US). **RUBINSTEIN, Israel** [IL/US]; 2999 Lexington Lane, Highland Park, IL 60035 (US).

(74) Agent: **WILLIAMS, Joseph, A., Jr.**; Marshall, Gerstein & Borun, 6300 Sears Tower, 233 S. Wacker Drive, Chicago, IL 60606-6357 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MATERIALS AND METHODS FOR MAKING IMPROVED LIPOSOME COMPOSITIONS

(57) Abstract: Provided are methods for treating autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, Cerebral palsy sleep disorder, feeding disorder and AIDS-associated dementias, using improved biologically active liposome products comprising a biologically active amphipathic compound in association with a liposome. Methods for producing the liposome products as well as methods of using the liposome products in therapeutic and diagnostic techniques are also provided.

WO 03/046145 A2

MATERIALS AND METHODS FOR MAKING IMPROVED LIPOSOME COMPOSITIONS

This application claims priority of U.S.
5 application Serial No.: 09/995,263, filed November 27,
2001.

BACKGROUND OF THE INVENTION

The present invention relates generally to
biologically active compounds and more specifically to
10 compounds, peptides and proteins which are amphipathic,
i.e., have both hydrophilic and hydrophobic portions.
Specifically, the invention relates to improved methods
for the delivery and presentation of amphipathic
compounds, peptides, and proteins, including analogs and
15 fragments alone and/or conjugated to other compound in
association with liposomes for both diagnostic and
therapeutic uses.

Of particular interest to the present invention
are the biologically active amphipathic peptides which
20 are members of the family of peptide compounds including
vasoactive intestinal peptide (VIP), growth hormone
releasing factor (GRF) and IL-2. More specifically, the
invention relates to improved therapeutic methods for
delivering peptides in the VIP/GRF or IL-2 family of
25 peptides to targeted tissues through use of improved
liposome compositions comprising a member of the VIP/GRF
or IL-2 family of peptides and biologically active
analogs, fragments and modulators thereof.

VIP is a 28-amino acid neuropeptide which is known to display a broad profile of biological actions and to activate multiple signal transducing pathways. See, Said, *Peptides* 5 (Suppl. 1):149-150 (1984) and Paul
5 and Ebadi, *Neurochem. Int.* 23:197-214 (1993). A Schiff-Edmundson projection of VIP as a π -helix reveals segregation of apolar and polar residues onto the opposite faces of the helix and that this amphipathic character is also evident when VIP is modeled as a
10 distorted α -helix, which is reported in Musso, et al., *Biochemistry* 27:8147-8181 (1988). A correlation between the helix-forming tendency of VIP analogs and their biological activity is described in Bodan et al.,
Bioorgan. Chem. 3:133-140 (1974). In pure water, the
15 spectral characteristics of VIP are consistent with those of a random coil. However, organic solvents and anionic lipids induce helical-information in the molecule. See, Robinson et al., *Biopolymers* 21:1217-1228 (1983); Hamed, et al., *Biopolymers* 22 :1003-1021 (1983); and Bodanszky,
20 et al., *Bioorganic Chem.* 3:133-140 (1974).

Short peptides capable of forming amphipathic helices are known to bind and penetrate lipid bilayers. See, Kaiser and Kezdy, *Ann. Rev. Biophys. Biophysical Chem.* 15:561-581 (1987) and Sansom, *Prog. Biophys. Molec.*
25 *Biol.* 55:139-235 (1991). Examples include model peptides like (LKKLLKL-), which are disclosed in DeGrado and Lear,

J. Am. Chem. Soc. 107:7684-7689 (1985), and the 26-residue bee venom peptide, melittin, disclosed in Watata and Gwozdziński, *Chem-Biol. Interactions* 82:135-149 (1992). Possible mechanisms for the binding include
5 alignment of peptide monomers parallel to the surface of the bilayer mediated by electrostatic interactions between polar amino acids and phospholipid head groups, and insertion of peptide aggregates into the apolar bilayer core, stabilized in part, by the hydrophobic
10 effect. See, Sansom, *Prog. Biophys. Molec. Biol.* 55:139-235 (1991).

VIP belongs to a family of homologous peptides, other members of which include peptide histidine isoleucine (PHI), peptide histidine methionine (PHM),
15 growth hormone releasing factor (GRF), hypocretins, pituitary adenylate cyclase activating peptide (PACAP), secretin, and glucagon. Like VIP, the other members of the VIP/GRF family of peptides, and biologically active analogs thereof, can form amphipathic helices capable of
20 binding lipid bilayers. The biological action of members of the VIP/GRF family of peptides are believed to be mediated by protein receptors expressed on the cell surface and intracellular receptors and it has recently been demonstrated that calmodulin is likely to be the
25 intracellular receptor for VIP [Stallwood, et al., *J.*

Bio. Chem. 267:19617-19621 (1992); and Stallwood, et al.,
FASEB J. 7:1054 (1993)].

The pleiotropic distribution of VIP is correlated with its involvement in a broad spectrum of biological activities, and growing evidence suggests that VIP plays a major role in regulating a variety of important functions in many organs. Physiological actions of VIP have been reported on the cardiovascular, respiratory, reproductive, digestive, immune, and central nervous systems, as well as metabolic, endocrine and neuroendocrine functions (for review, Said, *Trends Endocrinol. Metab.* 2:107-112 (1991)). In many cases, VIP acts as a neurotransmitter or neuromodulator and is released into the local circulation at small concentrations. Among the functions that VIP is believed to mediate or promote (Said, *Trends Endocrinol. Metab.* 2:107-112 (1991) Paul et al., *Neurochem. Int.* 23:197-214 (1993)), are vasodilation of cerebral, coronary, peripheral, and pulmonary blood vessels, linked to the regulation of vascular tone; the relaxation of gastrointestinal, uterine, and tracheobronchial smooth muscles; exocrine secretion, water and anions by intestinal, respiratory, and pancreatic epithelia; stimulation of the male and female activity and responses; release and regulation of neuroendocrine functions (renin release, melatonin secretion);

inhibition of the immune system (inhibition of platelet aggregation); and stimulation and protection of neuronal cells.

New VIP functions such as inhibition of
5 vascular smooth muscle cell growth, proliferation of
cultured human keratinocytes, the release of neutrophilic
and growth factors involved in cell differentiation and
ontogeny, and antioxidant properties have been recently
proposed but still need additional studies (Muller et
10 al., *Mol. Neurobiol.* 10:115-134 (1995); Said, *Trends
Endocrinol. Metab.* 2:107-112 (1991)).

Some human diseases today are known to be
associated with the deficiency in the release of VIP.
The deficiency of VIP has been linked to the pathogenesis
15 of several diseases, such as cystic fibrosis, diabetic
impotence, congenital megacolon in Hirschsprung's
disease, and achalasia of the esophagus. Furthermore,
VIP insufficiency may be a cause of bronchial
hyperactivity in asthmatic airways since VIP is known to
20 mediate airway relaxation in humans, and lung tissues of
asthmatic patients showed a selective absence of VIP
nerves (Ollerenshaw et al., *N. Engl. J. Med.* 320:1244-
1248 (1989)). Finally, Avidor et al., *Brain Res.*
503:304-307 (1989) observed an increase in brain VIP gene
25 expression in a rat model for spontaneous hypertension,

thought to be associated with the pathophysiology of the disease.

On the other hand, the excessive release of VIP has been linked to the pathogenesis of few diseases. One
5 of the pathological syndromes is pancreatic cholera, a watery diarrhea-hypochloremia-hypochloridria condition (Krejs, *Ann. N.Y. Acad. Sci.* 527:501-507 (1988)).

Certain tumors, especially pancreatic, bronchogenic, and neurogenic, have been associated with elevated
10 circulatory levels of VIP. In addition, it has also been suggested that increased levels of neuropeptides, including VIP, are found in neonatal blood of autistic children (Nelson, et al., *American Journal of Epidemiology* 151 (11 Supplement):pS3 June 1,2000).

15 Due to the numerous physiological actions of VIP, the use of VIP as a drug has been of growing interest. The potential therapeutic developments of VIP include treatment of diseases where regional blood flow is deprived. These include hypertension by reducing
20 systemic vascular overload, left ventricular failure, congestive heart failure, and coronary or peripheral ischemia. VIP infusion in man for 10 hours was shown to reduce total peripheral resistance by 30 % and increase forearm blood flow by 270 % (Frase et al., *Am. J. Cardiol.* 60:1356-1361 (1987)). Moreover, Smiley, *Am. J. Med. Sci.* 304:319-333 (1992) showed VIP-immunoreactive

nerves in the skin and plasma levels of VIP were found to be low in patients with scleroderma, thus treatment with VIP may restore this impaired response. Other diseases which could be treated by administration of VIP include treatment of asthmatic bronchospasm. VIP has been shown to protect against bronchoconstriction in asthmatic patients and as a relaxant of tracheobronchial smooth muscle (Morice et al., *Lancet* 26 2(8361):1225-1227 (1983)). Its anti-inflammatory properties could further enhance its therapeutic value in asthma (Said, *Biomed. Res.* 13 (Suppl. 2):257-262 (1992)). Administration of VIP could also be used in the prevention and/or reduction of tissue injury. The peptide has been described to prevent neuronal cell death produced by the external envelope protein gp120 of the human immunodeficiency virus *in vitro* (Gozes et al., *Mol. Neurobiol.* 3:201-236 (1989); Hökfelt, *Neuron.* 7:867-879 (1991)), which may lead to a potential therapy for AIDS dementia as well as treatment of Alzheimer's disease. Likewise, the acute inflammatory lung injury induced by a variety of insults including oxidant stress was diminished by the presence of VIP (Berisha et al., *Am. J. Physiol.* 259:L151-L155 (1990)). VIP added to certain pneumoplegic solutions was also shown to improve rat lung preservation before transplantation (Alessandrini et al., *Transplantation* 56:964-973 (1993)).

A major factor limiting *in vivo* administration of VIP has been its reduced bioavailability at target tissues mostly because of proteolytic degradation, hydrolysis, and/or a multiplicity of conformations adopted by the peptide. It has been speculated that intracellular delivery of VIP alone and/or VIP-calmodulin mixtures could bypass the requirement for cell-surface binding of the peptide and thus enhance the biological actions of the peptide. Provision of the peptides expressed in and on liposomes would possibly permit intracellular delivery, since lipid bilayers of liposomes are known to fuse with the plasma membrane of cells and deliver entrapped contents into the intracellular compartment.

Characterization of the structure and properties of liposomes led to many proposed uses for the vesicle as vehicles to effect targeted drug delivery, most of which failed to materialize for any of a number of various reasons. Most prominently, the therapeutic parenteral use of conventional liposomes was found to be limited because of rapid uptake into the reticuloendothelial system by mononuclear phagocytic cells [Gregoriadis and Ryman, *Eur. J. Biochem.* 27:485-491 (1972); Beaumier, and Hwang, *Biochem. Biophys. Acta* 731:23-30 (1983)]. Uptake by this particular cell type is advantageous under the limited conditions wherein the

targeted cell or tissue itself is part of the reticuloendothelial system, but uptake by phagocytic cells generally leads to degradation of compounds to be delivered, thereby posing a serious drawback to
5 delivering a compound to other cell or tissue types.

In attempts to overcome problems inherent to liposome drug delivery, research turned to several approaches including identification of compounds which would be released back into the blood following liposome
10 uptake by the reticuloendothelial system, alternatives to intravenous liposome administration, and use of various compounds, for example, cholesterol, to increase liposome stability in the bloodstream [Kirby, et al., *Biochem. J.* 186:591-598 (1980); Hwang, in Liposomes from biophysics
15 to therapeutics, Ostro (ed.) Marcel Decker: New York (1987) pp. 109-156; Beaumier, et al., *Res. Comm. Chem. Pathol. Pharmacol.* 39:227-232 (1983)]. Still other investigations examined various lipid compositions to form the liposome bilayer which more closely mimic the
20 naturally occurring bilayer of red blood cell. Such efforts led to increased liposome half-life in circulation [Allen and Chonn, *FEBS Lett.* 223:42-46 (1987); Gabizon and Papahadjopoulos, *Proc. Natl. Acad. Sci. (USA)* 85:6949-6953 (1988)].

25 PCT Publication WO 95/27496 and Gao, et al., *Life Science* 54:247-252 (1994) describe the use of

liposomes for delivery of VIP in comparison to its delivery in aqueous solution. Encapsulation of VIP in liposomes was found to protect the peptide from proteolytic degradation and to significantly enhance the ability of VIP and to effect a decrease in mean arterial pressure in comparison to VIP in aqueous solution in hypertensive hamsters. Liposome-associated VIP was found to significantly decrease mean arterial blood pressure for a period of approximately 12 minutes, with lowest blood pressure observed almost 5 minutes after initial administration. The publication also demonstrated binding of VIP in aqueous solution to liposomes and penetration of the peptide into the liposome bilayer. It was speculated that binding of VIP to liposomes might prevent loss of peptide activity either by partitioning of the peptide into the liposome membrane, stabilizing the peptide against proteolysis, or restricting the peptide in a biologically active conformation. Whatever the reason, encapsulation of VIP in liposomes enhanced *in vivo* biological activity of the peptide by both prolonging the effect and increasing the magnitude of the effect in lowering blood pressure of hypertensive hamsters. Nevertheless, there remains a desire in the art to provide further improvements in the therapeutic and diagnostic delivery of biologically active peptides such as VIP.

Of interest to the present invention is the observation of increased half-life of circulating protein through conjugation of the protein to a water soluble polymer [Nucci, et al., *Adv. Drug Del. Rev.* 6:133-151 (1991); Woodle, et al., *Proc. Intern. Symp. Control. Rel. Bioact. Mater.* 17:77-78 (1990)]. This observation led to the development of sterically stabilized liposomes (SSL) (also known as "PEG-liposomes") as an improved drug delivery system which has significantly minimized the occurrence of rapid clearance of liposomes from circulation. [Lasic and Martin, Stealth Liposomes, CRC Press, Inc., Boca Raton, FL (1995)]. SSL are polymer-coated liposomes, wherein the polymer, preferably polyethylene glycol (PEG), is covalently conjugated to one of the phospholipids and provides a hydrophilic cloud outside the vesicle bilayer. This steric barrier delays the recognition by opsonins, allowing SSL to remain in circulation much longer than conventional liposomes [Lasic and Martin, Stealth Liposomes, CRC Press, Inc., Boca Raton, FL (1995); Woodle, et al., *Biochem. Biophys. Acta* 1105:193-200 (1992); Litzinger, et al., *Biochem. Biophys. Acta* 1190:99-107 (1994); Bedu Addo, et al., *Pharm. Res.* 13:718-724 (1996)] and increases the pharmacological efficacy of encapsulated agents, as demonstrated for some chemotherapeutic and anti-infectious drugs [Lasic and Martin, Stealth Liposomes,

CRC Press, Inc., Boca Raton, FL (1995)]. Studies in this area have demonstrated that different factors affect circulation half-life of SSL, and ideally, the mean vesicle diameter should be under 200 nm, with PEG at a molecular weight of approximately 2,000 Da at a concentration of 5% (9-12) [Lasic and Martin, Stealth Liposomes, CRC Press, Inc., Boca Raton, FL (1995); Woodle, et al., *Biochem. Biophys. Acta* 1105:193-200 (1992); Litzinger, et al., *Biochem. Biophys. Acta* 1190:99-107 (1994); Bedu Addo, et al., *Pharm. Res.* 13:718-724 (1996)]. Preparation of SSL having these physical properties and including a bioactive compound, however, is not without complications as activity of the associated compound can be lost in preparation of SSL having desirable characteristics. This is particularly the case where an extrusion process is used to obtain small size liposomes with a narrow particle size distribution. For reasons which are not completely understood, such extrusion methods substantially reduce the biological activity peptide components associated with the liposomes. Accordingly, there remains a desire for improved liposome compositions which are sterically stable but which maintain the biological activity of associated peptide agents.

Also of interest to the present invention is the disclosure of PCT Publication WO 93/20802 which

relates to multilamellar liposomes useful for enhancement of organ imaging with acoustics (ultrasound). The publication describes various liposome compositions ranging in size from 0.8 to 10 microns including a tissue
5 specific ligand, such as an antibody, antibody fragment or a drug incorporated into the lipid bilayer, in order to facilitate tissue specific targeting. The oligolamellar liposomes are prepared by processes such as lyophilization, repeated freeze-thaw, or modified double
10 emulsion techniques to produce internally separated bilayers. Preferred liposomes are said to range from 1.0 to 3.0 microns in diameter. It has thus far been more difficult to produce liposomes which are readily detectable by conventional ultrasound techniques less
15 than about 0.5 microns in size. Accordingly, there remains a desire for improved liposome compositions which may be efficiently produced and which have average particle sizes less than about 0.5 microns. Moreover, there remains a desire for improved liposome compositions
20 which are efficiently produced, stable *in vivo*, and provide a higher degree of resolution upon acoustic imaging.

Thus, there exists a need in the art to provide further improvements in the use of liposome technology
25 for the therapeutic and diagnostic administration of bioactive molecules. More specifically, there remains a

desire in the art for improved methods for administration of amphipathic peptides including, but not limited to, members of the VIP/GRF family of peptides in liposomes in order to achieve a more prolonged and effective
5 therapeutic effect.

SUMMARY OF THE INVENTION

The present invention provides methods of treating a variety of disease states using liposome compositions prepared as described in U.S. Patent
10 Application 6, 197,333, issued March 6 2001, and PCT Publication No. WO 97/35561, published October 2, 1997, both of which are incorporated herein by reference in their entireties. Methods of the invention provide therapeutic treatment for disease states as described
15 herein. The liposomal formulations of the invention deliver and enhance bioactivity of the biologically active compounds, peptides, and proteins, including analogs and fragments thereof, alone and/or conjugated to other compounds in a manner which provides improvements
20 in the efficacy and duration of the biological effects of the associated peptides. Increased efficacy and duration of the biological effect is believed to result, at least in part, from interaction of the compound with the liposome in such a manner that the compound attains, and
25 is maintained in, an active or more active conformation than the compound in an aqueous environment. The

invention thus overcomes the problems associated with previous liposomal formulations, such as, but not limited to, uptake by the reticuloendothelial system, degradation of the compound, or delivery of the compound in an inactive conformation. Particularly preferred amphipathic compounds useful with the invention include any member of the vasoactive intestinal peptide (VIP)/growth hormone releasing factor (GRF) or IL-2 family of peptides which includes biologically active analogs thereof. The mammalian and non-mammalian VIP/GRF family of peptides includes functional analogs of VIP and GRF, peptide histidine isoleucine (PHI), peptide histidine methionine (PHM), growth hormone releasing factor (GRF), hypocretins, pituitary adenylate cyclase activating peptide (PACAP), secretin, and glucagon. Preferred methods of the invention utilize liposome compositions comprising a member of the VIP/glucagon/secretin family of peptides including peptide fragments and analogs. Also of interest to the present invention are the biologically active amphipathic peptides which are members of the family of peptide compounds including, but not limited to, gastric inhibitory hormone (GIP), hemodermin, the growth hormone releasing hormone (GHRH), sauvagine and urotensin I, secretin, glucagon, galanin, endothelin, calcitonin, α_1 -proteinase inhibitor, angiotensin II, corticotropin

releasing factor, antibacterial peptides and proteins in general, surfactant peptides and proteins, α -MSH, adrenomedullin, ANF, IGF-1, α 2 amylin, orphanin, and orexin. Other peptides of interest include neuropeptides, which serve as integrative chemical messengers, conveying information from one discrete neuronal population to another. Furthermore, it is becoming evident that neuropeptides are involved in coupling transductive events from neurons to glial and to immune cells. Major areas of neuropeptide research encompass pain and analgesia, appetite control, inflammation, mood and affective behavior. In addition the invention contemplates neuropeptides as discussed herein, and other neuropeptides including, but are not limited to, heliospectins I or II, neuropeptide Y (NPY), neuropeptide YY (NPYY), including neuropeptide fragments 2-36 and related fragments, ACTH, calcitonin, GAP (GnRH precursor molecule), glutamate-decarboxylase, keyhole limpet hemocyanin, leucin-enkephalin, mesotocin, methionin-enkephalin, neurotensin, peroxydase, somatostatin, substance P, vasopressin, and vasotocin. The biologically active peptide products of the invention may be utilized in a wide variety of therapeutic and diagnostic uses wherein it is desired to deliver a high level of biologically active compound or to detect targeted

delivery of the liposome product as will be described below.

In one aspect, the invention provides methods of treating a disease state selected from the group
5 consisting of autism, multiple sclerosis, eneuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, cerebral palsy (CP) sleep disorder, feeding disorder and AIDS-associated dementias, comprising the step of administering to an individual
10 suffering from the disease state an amount of a liposome composition effective to alleviate conditions associated with the disease state, said liposome composition prepared by a method comprising the steps of: a) mixing a combination of lipids wherein said combination includes
15 at least one lipid component covalently bonded to a water-soluble polymer; b) forming sterically stabilized liposomes from said combination of lipids; c) obtaining liposomes having an average diameter of less than about 300 nm; and d) incubating liposomes from step (c) with a
20 biologically active amphipathic compound under conditions in which said compound becomes associated with said liposomes from step (c) in an active conformation, wherein at least one amphipathic compound is a member of the VIP/glucagon/secretin family of peptides including
25 peptide fragments and analogs. The invention also contemplates the use of other neuropeptides including

neuropeptide Y (NPY), neuropeptide YY (NPYY), ACTH, calcitonin, GAP (GnRH precursor molecule), glutamate-decarboxylase, GnRH / GL, keyhole limpet hemocyanin, leucin-enkephalin, mesotocin, methionin-enkephalin, neurotensin, peroxydase, somatostatin, substance P, vasopressin, and vasotocin. In other embodiments, the targeting compound can be heliospectins I or II or any member of the neuropeptide family. In one embodiment, methods of the invention employ active liposome compositions which comprise unilamellar liposomes. In another embodiment, these liposome compositions are multivesicular liposomes. In aspects of the invention wherein the liposome compositions are multivesicular liposomes, methods are provided wherein the liposome compositions produced by carrying out the steps of sequentially dehydrating and rehydrating liposomes obtained in step (c) with said biologically active peptide.

Preferably, methods utilize liposome compositions wherein the water soluble polymer is polyethylene glycol (PEG). Also preferred are methods wherein the amphipathic compound is characterized by having one or more α - or π -helical domains in its biologically active conformation. In more preferred methods, the compound is a member of the vasoactive intestinal peptide (VIP)/growth hormone releasing factor

(GRF) family of peptides. In another aspect, the compound is a member of the VIP/glucagon/secretin family of peptides, including peptide fragments and analogs thereof.

5 Methods of the invention include those wherein liposomes obtained in step (c) have an average diameter or less than about 200 nm. In a preferred aspect, the liposomes obtained in step (c) have an average diameter or less than about 100 nm. In one aspect, the liposomes
10 are obtained in step (c) by extrusion to form liposomes having a selected average diameter. Alternatively, methods employ liposome which are obtained in step (c) by size selection.

 In one aspect, methods of the invention utilize
15 liposome which are formed from a combination of lipids that consists of distearoyl-phosphatidylethanolamine covalently bonded to PEG (PEG-DSPE), phosphatidylcholine (PC), and phosphatidylglycerol (PG) in further combination cholesterol (Chol). In a preferred method,
20 these lipids are combined with cholesterol in a PEG-DSPE:PC:PG:Chol molar ratio of 0.5:5:1:3.5.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides improved methods of preparing biologically active liposome products
25 comprising biologically active amphipathic compounds in association with a liposome. The preferred amphipathic

compounds are characterized by having hydrophilic and hydrophobic domains segregated to the extent that the hydrophobic domain is capable of associating with or within the liposome bilayer. Compounds of the invention preferably attain a biologically active conformation in association with or within the liposome bilayer. Active conformations are those in which the desired compound is most likely to be capable of effecting its normal biological activity, for example, through receptor or ligand recognition and binding. Compounds of the invention may be characterized by having one or more discrete α - or π -helical domains which segregate the hydrophobic and hydrophilic domains. Preferred compounds of the invention are members of the VIP/GRF or IL-2 peptide family. The most preferred compound of the invention is a member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs. While biologically active compounds are associated with the liposome bilayer, the association is not irreversible and the compound may be released either quickly or over time from association with the liposome, depending on properties of the liposome and the compound.

In contrast to prior art methods which frequently include the step of extruding peptide-containing liposomes through membranes and filters to obtain liposomes of a desired size, the liposomes

according to the present invention are obtained having a diameter of less than 300 nm prior to being contacted with the active compound ingredient. Liposomes of this size may be obtained using an extrusion step which

5 modifies liposomes, thereby reducing the size of the liposomes to a preferred average diameter prior to being incubated with the biologically active compound.

Alternatively, liposomes of the desired size may be selected using techniques such as filtration or other

10 size selection techniques. While the size-selected liposomes of the invention should have an average diameter of less than about 300 nm, it is preferred that they are selected to have an average diameter of less than about 200 nm with an average diameter of less than

15 about 100 nm being particularly preferred. When the biologically active liposome product is a unilamellar liposome, it preferably is selected to have an average diameter of less than about 200 nm. The most preferred unilamellar liposomes of the invention have an average

20 diameter of less than about 100 nm. It is understood, however, that multivesicular liposomes of the invention derived from smaller unilamellar liposomes will generally be larger and may have an average diameter of about less than 1000 nm. Preferred multivesicular liposomes of the

25 invention have an average diameter of less than about 800 nm, and less than about 500 nm while most preferred

multivesicular liposomes of the invention have an average diameter of less than about 300 nm.

Liposomes according to the invention may be produced from combinations of lipid materials well known and routinely utilized in the art to produce liposomes and including at least one lipid component covalently bonded to a water-soluble polymer. Lipids may include relatively rigid varieties, such as sphingomyelin, or fluid types, such as phospholipids having unsaturated acyl chains. Polymers of the invention may include any compounds known and routinely utilized in the art of SSL technology and technologies which are useful for increasing circulatory half-life for proteins, including for example polyvinyl alcohol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, polyacrylamide, polyglycerol, polyaxozlines, or synthetic lipids with polymeric headgroups. The most preferred polymer of the invention is PEG at a molecular weight between 1000 and 5000. Preferred lipids for producing liposomes according to the invention include distearoyl-phosphatidylethanolamine covalently bonded to PEG (PEG-DSPE), phosphatidylcholine (PC), and phosphatidylglycerol (PG) in further combination with cholesterol (Chol). According to a preferred embodiment of the invention, a combination of lipids and cholesterol for producing the

liposomes of the invention comprise a PEG-DSPE:PC:PG:Chol molar ratio of 0.5:5:1:3.5.

The liposomes produced according to the methods of the invention are characterized by improved stability
5 and biological activity and are useful in a variety of therapeutic, diagnostic and/or cosmetic applications.

According to one embodiment, the invention comprehends a composition comprising a biologically active liposome product wherein said biologically active amphipathic
10 compound has anti-oxidant activity, anti-aging, anti-wrinkle formation or wound healing capacity.

Compositions of this type may be of cosmetic or therapeutic nature. The preferred cosmetic composition includes a biologically active member of the
15 VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs. The invention also provides an oral controlled release preparation for the treatment of a gastrointestinal disorder wherein said preparative method further comprises the step of
20 encapsulating the biologically active liposome product in an enteric coating. The oral controlled release preparation is useful in a variety of gastrointestinal disorders including those selected from the group consisting of inflammatory bowel disorder, chronic
25 constipation, Hirschprung's disease, achalasia, infantile hypertrophic pyloric stenosis, and ulcers. The preferred

oral preparation includes a biologically active member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs. Liposome preparations comprising a biologically active member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs are also a promising therapeutic agent for conditions such as asthma, systemic and pulmonary hypertension, scleroderma, myocardial ischemia, impotence and baldness. The invention further provides methods for preserving a bodily organ, tissue, or cell type for storage and transplantation in a recipient comprising the step of incubating said organ in a liposome composition comprising a member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs.

The invention further provides methods of treating autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, CP sleep disorder, feeding disorder and AIDS-associated dementia by administering a amount of a composition of the invention effective to ameliorate pathological conditions associated with autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, CP sleep disorder, feeding disorder and AIDS-associated dementias

The invention further provides methods of administering a biologically active amphipathic compound to a target tissue comprising the steps of: preparing a biologically active liposome product comprising a
5 biologically active amphipathic compound in association with a liposome according to the methods of the invention and administering a therapeutically effective amount of the liposome product to said target tissue. The liposome products of the invention may be administered
10 intravenously, intraarterially, intranasally such as by aerosol administration, nebulization, inhalation, or insufflation, intratracheally, intra-articularly, orally, transdermally, subcutaneously, topically onto mucous membranes, such as, but not limited to, oral mucosa,
15 lower gastrointestinal mucosa and conjunctiva, and directly onto target tissues.

An exemplary regiment in the treatment, for example, of autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain
20 ischemia, stroke, CP sleep disorder, feeding disorder and AIDS-associated dementias, would include administration of from 0.001 mg/kg body weight to about 1000 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.1 mg/kg to about 100 mg/kg, about 1.0 mg/kg to about 50 mg/kg, or
25 from about 1 mg/kg to about 20 mg/kg, given in daily doses or in equivalent doses at longer or shorter

intervals, e.g., every other day, twice weekly, weekly, monthly, semi-annually, or even twice or three times daily. Alternatively, dosages may be measured in international units (IU) ranging from about 0.001 IU/kg body weight to about 1000 IU/kg, from about 0.01 IU/kg to about 100 IU/kg, from about 0.1 IU/kg to about 100 IU/kg, from about 1 IU/kg to about 100 IU/kg, from about 1 IU/kg to about 50 IU/kg, or from about 1 IU/kg to about 20 IU/kg. Administration may be oral, intravenous, subcutaneous, intranasal, inhalation, transdermal, transmucosal, or by any other route discussed herein.

Biologically active compounds in therapeutic methods can be administered at significantly reduced dosage levels as compared to administration of the compound alone, particularly wherein the compound has a particularly short half life or lowered bioactivity in circulation. For example, VIP in association with SSL can be expected to exhibit enhanced and prolonged bioactivity in comparison to VIP administered alone. Generally, the biologically effective amount of VIP in SSL is about 50 to 75 percent less by weight than the biologically effective amount of VIP in aqueous solution. Regardless of which bioactive compound is associated with SSL, the liposome product must be tested in order to determine a biologically effective amount required to achieve the same result effected by the compound

administered by conventionally means. The worker of ordinary skill in the art would realize that the biologically effective amount of a particular compound when delivered by conventional means would serve as a starting point in the determination of an effective amount of the compound in SSL. It would therefore be highly predictive that the same and lesser dosages in SSL would be effective as well and merely routine to determine the minimum dosage required to achieve a desired biological effect. In the case of VIP administration, for example, if conventional administration would require a dosage of 20 mg, VIP in SSL would likely require 5 to 10 mg in order to achieve the same effect. Typically, a biologically effective amount of intravenously administered VIP would total 0.01 to 50 mg daily or 0.1 to 500 mg VIP in capsule form.

Association of a biologically active compound with SSL of the invention would be expected to increase the magnitude of the biological effects of the compound from about 50 to 100% over the effects observed following administration of the compound alone. Likewise, association with SSL of the invention would be expected to invoke a longer lasting biological effect.

The invention further provides improved diagnostic compositions comprising multivesicular biologically active liposome products and methods for

their use comprising the steps of: preparing a biologically active liposome product comprising a biologically active amphipathic compound in association with a multilamellar liposome prepared according to the methods of the invention; administering a diagnostically effective amount of the liposome product to a target tissue; and detecting uptake or interaction of the liposome product at the target tissue. According to one aspect of the invention, the target tissue is a tumor.

10 In one aspect of the method, the liposome product is detectably labeled with a label selected from the group including a radioactive label, a fluorescent label, a non-fluorescent label, a dye, or a compound which enhances magnetic resonance imaging (MRI). According to

15 the preferred embodiment of the invention, the liposome product is detected by acoustic reflectivity. Diagnostic liposome products for detection by acoustic imaging generally have an average diameter of less than about 1000 nm, but preferably, the diagnostic liposome products

20 have an average diameter of less than 600 nm and most preferably have an average diameter of less than about 300 nm.

The invention also provides use of a biologically active liposome product comprising a biologically active amphipathic compound and produced according to methods of the invention for the treatment

25

of inflammation, chronic obstruction pulmonary disease, increased secretion of mucin, acute food impaction, rhinitis, Kartagener's syndrome, cystic fibrosis, bronchiectasis, hypertension, allergy, Alzheimer's disease, cerebral palsy, stroke, atherosclerosis, inflammatory bowel disorder, chronic constipation, Hirschprung's disease, achalasia, infantile hypertrophic pyloric stenosis, ulcers, to enhance or decrease cell proliferation, prevent apoptosis, to promote wound healing in a body organ or tissue, and to prevent cell, organ and tissue rejection, autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, cerebral palsy (CP) sleep disorder, feeding disorder and AIDS-associated dementias, impotence and female arousal sexual dysfunction. As discussed herein, neonatal blood from autistic children has been shown to have increased levels of neuropeptides, including a member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs. One possible explanation for this observation is that an endogenously expressed member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs may be biologically inactive (or partially inactivated). Because the circulating peptide is inactive, and its effects not realized, additional

peptide is continually produced to achieve the desired effect. Administration of a member of the VIP/glucagon/secretin family of peptides including peptide fragments and analogs in a composition of the invention, which maintains a member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs in a biologically active conformation, would be expected to actuate biological processes dependent on a member of the VIP/glucagon/secretin or IL-2 family of peptides including peptide fragments and analogs that the endogenous inactive peptide cannot. As an alternative explanation, VIP receptors are rendered dysfunctional to the extent that native VIP cannot interact, whereas VIP in a micelle composition of the invention is able to either recognize and interact with the modified receptor, or able to effect its biological activity through a non-receptor mediated pathway.

US Patent 6,197,333, the disclosure of which is hereby incorporated described results described results of use of VIP associated liposomes according to the invention. Specifically, VIP-PEG-liposomes were prepared as follows. DSPE linked to PEG (molecular weight 1,900), PG, PC, and cholesterol (molar ration 0.5:1:5:3.5) were dissolved in chloroform in a round bottom flask. The solution was dried overnight in a rotoevaporator and the

resulting film desiccated overnight. The lipid film was rehydrated with saline, pH 6-7, while vortexing, and then sonicated for at least 5 minutes. The liposome preparation thus formed was extruded through stacked
5 Nucleopore filters with pore sizes 200 nm, 100 nm, and 50 nm, respectively, until the mean size of PEG-liposome was 80-100 nm as determined by quasi elastic light scattering. VIP and trehalose, a cryoprotectant, were added to the extruded liposome preparation in
10 polypropylene tubes, the mixture snap-freezed in ethanol- or acetone-dry ice bath for at least 20 minutes, and lyophilized overnight under similar conditions. Free VIP was separated from VIP-PEG-liposomes using Bio Gel A-5m column chromatography. The size of the PEG-liposomes in
15 original solution and VIP-PEG-liposomes was determined by quasi elastic light scattering. Lipid concentration in PEG-liposomes in the original solution and in VIP-PEG-liposomes was determined by inorganic phosphate assay. VIP concentration in VIP-PEG-liposomes was determined by
20 an ELISA assay.

To determine VIP concentration in VIP-PEG-liposomes, 1% sodium dodecyl sulfate, a detergent, was added to an aliquot of the VIP-PEG-liposome preparation to release associated VIP before assay. PEG-liposome and
25 1% sodium dodecyl sulfate alone did not interfere with the ELISA assay. Non-limiting examples from preliminary

experiments using these preparations indicated increased and prolonged biological potency to target tissues of mammals as described below.

US Patent 6,197,333 further disclosed that a bolus intravenous injection of 1.0 nmol VIP-PEG-liposome compound acted to decrease mean arterial pressure (MAP) in hamsters with spontaneous hypertension. The results are reproduced herein as Figures 2A and 2B; Figure 2A showing the actual decrease on arterial pressure and Figure 2B showing the percent change. Data are mean values \pm one standard error of the mean; an asterisk indicates statistically significant values compared to control with p value less than 0.05. Results indicated a significant, gradual and sustained decrease in mean arterial pressure reaching a nadir within 2 hours after injection of VIP-PEG-liposomes which lasted throughout the observation period of 7 hours.

According to another experiment, normotensive hamsters were suffused onto the cheek pouch for 7 minutes with 0.1 nmol VIP-PEG-liposome composition which produced a significant increase in mean arterial diameter *in situ*. The results of this experiment are shown in Figure 3 with data and significance indicated for results in Figures 2A and 2B above. A significant increase in arteriolar diameter from baseline was observed with maximal effect within 5 minutes from the start of suffusion. Arterial

diameter returned to baseline 9 minutes after suffusion was discontinued.

In still another experiment, 1.0 nmol VIP-PEG-liposome composition was superfused for 30 minutes into
5 the nostril of a hypertensive hamster which resulted in a decrease in arterial pressure that persisted at least 150 minutes. These results are shown in Figure 4. A gradual and sustained decrease in mean arterial pressure to the normal range was detected that lasted throughout the
10 observation period of 2.5 hours.

Finally, as another experiment the effect of VIP-PEG-liposomes on neutrophil chemotaxis was examined using a two chamber apparatus routinely employed for *in vitro* analysis of chemotaxis. The results of the
15 experiment are shown in Figure 5. Neutrophil migration from the upper chamber into the lower chamber in response to formyl-methionyl-leucyl-phenylalanyl (fmlp) peptide in the lower chamber was initially established at a baseline control. Neutrophil migration against media (Hank's
20 balanced salt solution, HBSS) and VIP alone in the lower chamber was shown to be negligible, and minor levels of neutrophil migration were detected against VIP-PEG-liposomes and PEG-liposome in the lower chamber. When neutrophils and VIP were added together in the upper
25 chamber, significant migration was observed against fmlp in the lower chamber, with slightly lower levels of cell

migration observed against fmlp with neutrophils and PEG-liposomes together in the upper chamber. Finally, neutrophil migration against fmlp was reduced to almost negligible levels when VIP-PEG-liposomes were added with the cells in the upper chamber. These results indicated that VIP-PEG-liposomes were capable of chemotactic inhibition of neutrophil migration in response to fmlp.

"Inflammation" as used herein refers to a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off (sequester) both the injurious agent and the injured tissue. Inflammation is notably associated with influx of leukocytes and or neutrophil chemotaxis. Inflammation may result from infection with pathogenic organisms and viruses and from noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune response to foreign antigen, and autoimmune responses. Accordingly, inflammatory disorders amenable to the invention encompass disorders associated with reactions of the specific defense system as well as with reactions of the non-specific defense system.

As used herein, the term "specific defense system" refers to the component of the immune system that reacts to the presence of specific antigens. Examples of inflammation resulting from a response of the specific

defense system include the classical response to foreign antigens, autoimmune diseases, and delayed type hypersensitivity response mediated by T-cells. Chronic inflammatory diseases, the rejection of solid
5 transplanted tissue and organs, e.g., kidney and bone marrow transplants, and graft versus host disease (GVHD), are further examples of inflammatory reactions of the specific defense system.

The term "non-specific defense system" as used
10 herein refers to inflammatory disorders that are mediated by leukocytes that are incapable of immunological memory (e.g., granulocytes, macrophages). Examples of inflammation that result, at least in part, from a reaction of the non-specific defense system include
15 inflammation associated with conditions such as adult (acute) respiratory distress syndrome (ARDS) or multiple organ injury syndromes; reperfusion injury; acute glomerulonephritis; reactive arthritis; dermatoses with acute inflammatory components; acute purulent meningitis
20 or other central nervous system inflammatory disorders such as stroke; thermal injury; inflammatory bowel disease; granulocyte transfusion associated syndromes; and cytokine-induced toxicity.

"Autoimmune disease" as used herein refers to
25 any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the

body's own constituents. "Allergic disease" as used herein refers to any symptoms, tissue damage, or loss of tissue function resulting from allergy. "Arthritic disease" as used herein refers to any disease that is

5 characterized by inflammatory lesions of the joints attributable to a variety of etiologies. "Dermatitis" as used herein refers to any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies.

10 "Transplant rejection" as used herein refers to any immune reaction directed against grafted tissue (including organs or cells (e.g., bone marrow), characterized by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and

15 thrombocytopenia.

The therapeutic methods of the present invention include methods for the amelioration of disorders associated with inflammatory cell activation. "Inflammatory cell activation" refers to the induction by

20 a stimulus (including, but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or cell surface

25 expression of new or increased numbers of mediators (including, but not limited to, major histocompatibility

antigens or cell adhesion molecules) in inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (polymorphonuclear leukocytes including neutrophils, 5 basophils, and eosinophils), mast cells, dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons skilled in the art that the activation of one or a combination of these phenotypes in these cells can contribute to the initiation, 10 perpetuation, or exacerbation of an inflammatory disorder.

The present invention enables methods of treating various diseases associated with or characterized by inflammation, for example, arthritic 15 diseases such as rheumatoid arthritis, osteoarthritis, gouty arthritis, spondylitis; Behcet disease; sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome; multiple organ injury syndrome secondary to septicemia, trauma, or 20 hemorrhage; ophthalmic disorders such as allergic conjunctivitis, vernal conjunctivitis, uveitis, and thyroid-associated ophthalmopathy; eosinophilic granuloma; pulmonary or respiratory disorders such as asthma, chronic bronchitis, allergic rhinitis, ARDS, 25 chronic pulmonary inflammatory disease (e.g., chronic obstructive pulmonary disease), silicosis, pulmonary

sarcoidosis, pleurisy, alveolitis, vasculitis, pneumonia, bronchiectasis, and pulmonary oxygen toxicity; reperfusion injury of the myocardium, brain, or extremities; fibrosis such as cystic fibrosis; keloid formation or scar tissue formation; atherosclerosis; 5 autoimmune diseases such as systemic lupus erythematosus (SLE), autoimmune thyroiditis, multiple sclerosis, some forms of diabetes, and Reynaud's syndrome; transplant rejection disorders such as GVHD and allograft rejection; 10 chronic glomerulonephritis; inflammatory bowel diseases such as Crohn's disease, ulcerative colitis and necrotizing enterocolitis; inflammatory dermatoses such as contact dermatitis, atopic dermatitis, psoriasis, or urticaria; fever and myalgias due to infection; central 15 or peripheral nervous system inflammatory disorders such as meningitis, encephalitis, and brain or spinal cord injury due to minor trauma; Sjorgren's syndrome; diseases involving leukocyte diapedesis; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex mediated 20 diseases; hypovolemic shock; Type I diabetes mellitus; acute and delayed hypersensitivity; disease states due to leukocyte dyscrasia and metastasis; thermal injury; granulocyte transfusion associated syndromes; and cytokine-induced toxicity.

25 Autoimmune disorders which may be treated using a protein of the present invention include, for example,

connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft versus host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems.

The present invention also provides methods of treating cancer in an animal, comprising administering to the animal an effective amount of a compound that inhibits DNA-PK activity. The invention is further directed to methods of inhibiting cancer cell growth, including processes of cellular proliferation, invasiveness, and metastasis in biological systems.

Methods include use of a compound of the invention as an

inhibitor of cancer cell growth. Preferably, the methods are employed to inhibit or reduce cancer cell growth, invasiveness, metastasis, or tumor incidence in living animals, such as mammals. Methods of the invention are
5 also readily adaptable for use in assay systems, e.g., assaying cancer cell growth and properties thereof, as well as identifying compounds that affect cancer cell growth.

Compounds of the invention are possess one or
10 more desirable but unexpected combinations of properties, including increased activity and/or solubility, and reduction of negative side effects. These compounds have been found to inhibit cancer growth, including proliferation, invasiveness, and metastasis, thereby
15 rendering them particularly desirable for the treatment of cancer. In particular, compounds of the invention exhibit cancer-inhibitory properties at concentrations that appear to be substantially free of side effects. These compounds are therefore useful for extended
20 treatment protocols, where the use of conventional chemotherapeutic compounds can exhibit undesirable side effects. For example, the coadministration of a compound of the invention with another, more toxic, chemotherapeutic agent can achieve beneficial inhibition
25 of a cancer, while effectively reducing the toxic side effects in the patient.

In addition, the properties of hydrophilicity and hydrophobicity of the compounds of the invention are well balanced, thereby enhancing their utility for both in vitro and especially in vivo uses, while other
5 compounds lacking such balance are of substantially less utility. Specifically, compounds of the invention have an appropriate degree of solubility in aqueous media which permits absorption and bioavailability in the body, while also having a degree of solubility in lipids which
10 permits the compounds to traverse the cell membrane to a putative site of action. Thus, compounds of the invention are maximally effective when they can be delivered to the site of the tumor and they enter the tumor cells.

15 The cancers treatable by methods of the present invention preferably occur in mammals. Mammals include, for example, humans and other primates, as well as pet or companion animals such as dogs and cats, laboratory animals such as rats, mice and rabbits, and farm animals
20 such as horses, pigs, sheep, and cattle.

Tumors or neoplasms include growths of tissue cells in which the multiplication of the cells is uncontrolled and progressive. Some such growths are benign, but others are termed "malignant" and may lead to
25 death of the organism. Malignant neoplasms or "cancers" are distinguished from benign growths in that, in

addition to exhibiting aggressive cellular proliferation, they may invade surrounding tissues and metastasize. Moreover, malignant neoplasms are characterized in that they show a greater loss of differentiation (greater
5 "dedifferentiation"), and of their organization relative to one another and their surrounding tissues. This property is also called "anaplasia."

Neoplasms treatable by the present invention also include solid tumors, i.e., carcinomas and sarcomas.
10 Carcinomas include those malignant neoplasms derived from epithelial cells which infiltrate (invade) the surrounding tissues and give rise to metastases. Adenocarcinomas are carcinomas derived from glandular tissue, or which form recognizable glandular structures.
15 Another broad category of cancers includes sarcomas, which are tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue. The invention also enables treatment of cancers of the myeloid or lymphoid systems, including leukemias,
20 lymphomas and other cancers that typically do not present as a tumor mass, but are distributed in the vascular or lymphoreticular systems.

The type of cancer or tumor cells amenable to treatment according to the invention include, for
25 example, ACTH-producing tumor, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the

adrenal cortex, bladder cancer, brain cancer, breast
cancer, cervical cancer, chronic lymphocytic leukemia,
chronic myelocytic leukemia, colorectal cancer, cutaneous
T-cell lymphoma, endometrial cancer, esophageal cancer,
5 Ewing's sarcoma, gallbladder cancer, hairy cell leukemia,
head and neck cancer, Hodgkin's lymphoma, Kaposi's
sarcoma, kidney cancer, liver cancer, lung cancer (small
and non-small cell), malignant peritoneal effusion,
malignant pleural effusion, melanoma, mesothelioma,
10 multiple myeloma, neuroblastoma, glioma, non-Hodgkin's
lymphoma, osteosarcoma, ovarian cancer, ovarian (germ
cell) cancer, pancreatic cancer, penile cancer, prostate
cancer, retinoblastoma, skin cancer, soft tissue sarcoma,
squamous cell carcinomas, stomach cancer, testicular
15 cancer, thyroid cancer, trophoblastic neoplasms, uterine
cancer, vaginal cancer, cancer of the vulva, and Wilms's
tumor.

The invention is particularly illustrated
herein in reference to treatment of certain types of
20 experimentally defined cancers. In these illustrative
treatments, standard state-of-the-art in vitro and in
vivo models have been used. These methods can be used to
identify agents that can be expected to be efficacious in
in vivo treatment regimens. However, it will be
25 understood that the method of the invention is not
limited to the treatment of these tumor types, but

extends to any solid tumor derived from any organ system. Cancers whose invasiveness or metastasis is associated with DNA-PK expression or activity are especially susceptible to being inhibited or even induced to regress
5 by means of the invention.

The invention further relates to radiosensitizing tumor cells. The term "radiosensitizer," as used herein, is defined as a molecule, preferably a low molecular weight molecule,
10 administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to be radiosensitized to electromagnetic radiation and/or to promote the treatment of diseases that are treatable with electromagnetic radiation. Diseases that are treatable
15 with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells.

Electromagnetic radiation treatment of other diseases not listed herein is also contemplated by the
20 present invention. The terms "electromagnetic radiation" and "radiation" as used herein include, but are not limited to, radiation having the wavelength of 10-20 to 100 meters. Preferred embodiments of the present invention employ the electromagnetic radiation of: gamma-
25 radiation (10-20 to 10-13 m), X-ray radiation (10-12 to 10-9 m), ultraviolet light (10 nm to 400 nm), visible

light (400 nm to 700 nm), infrared radiation (700 nm to 1.0 mm), and microwave radiation (1 mm to 30 cm).

Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of electromagnetic radiation. Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature including: hypoxic cell radiosensitizers, e.g., 2-nitroimidazole compounds, and benzotriazine dioxide compounds) promote the reoxygenation of hypoxic tissue and/or catalyze the generation of damaging oxygen radicals; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogs of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation ion-induced breaking of DNA molecules and/or prevent the normal DNA repair mechanisms; and various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of disease.

Many cancer treatment protocols currently employ radiosensitizers activated by the electromagnetic radiation of X-rays. Examples of X-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylnisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-

iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FUdR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.

5 Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin(r),
10 benzoporphyrin derivatives, NPe6, tin etioporphyrin (SnET2), pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.

15 Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds that promote the incorporation of radiosensitizers to the target cells; compounds that
20 control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents that act on the tumor with or without additional radiation; or other therapeutically effective compounds for treating cancer or other disease. Examples of additional
25 therapeutic agents that may be used in conjunction with radiosensitizers include, but are not limited to: 5-

fluorouracil (5-FU), leucovorin, 5(-amino-5(-
deoxythymidine, oxygen, carbogen, red cell transfusions,
perfluorocarbons (e.g., Fluosol(r)-DA), 2,3-DPG, BW12C,
calcium channel blockers, pentoxifylline, anti-
5 angiogenesis compounds, hydralazine, and L-BSO. Examples
of chemotherapeutic agents that may be used in
conjunction with radiosensitizers include, but are not
limited to: adriamycin, camptothecin, carboplatin,
cisplatin, daunorubicin, doxorubicin, interferon (alpha,
10 beta, gamma), interleukin 2, irinotecan, docetaxel,
paclitaxel, topotecan, and therapeutically effective
analogues and derivatives of the same.

The invention can also be practiced by
including with a compound of the invention another anti-
15 cancer chemotherapeutic agent, such as any conventional
chemotherapeutic agent. The combination of the
tetracycline compound with such other agents can
potentiate the chemotherapeutic protocol. Numerous
chemotherapeutic protocols will present themselves in the
20 mind of the skilled practitioner as being capable of
incorporation into the method of the invention. Any
chemotherapeutic agent can be used, including alkylating
agents, antimetabolites, hormones and antagonists,
radioisotopes, as well as natural products. For example,
25 the compound of the invention can be administered with
antibiotics such as doxorubicin and other anthracycline

analogs, nitrogen mustards such as cyclophosphamide, pyrimidine analogs such as 5-fluorouracil, cisplatin, hydroxyurea, paclitaxel (Taxol®) and its natural and synthetic derivatives, and the like. As another example, in the case of mixed tumors, such as adenocarcinoma of the breast, where the tumors include gonadotropin-dependent and gonadotropin-independent cells, the compound can be administered in conjunction with leuprolide or goserelin (synthetic peptide analogs of LH-10 RH). Other antineoplastic protocols include the use of a tetracycline compound with another treatment modality, e.g., surgery, radiation, etc., also referred to herein as "adjunct antineoplastic modalities." Thus, the method of the invention can be employed with such conventional 15 regimens with the benefit of reducing side effects and enhancing efficacy.

Therapeutic compositions are within the scope of the present invention. Such pharmaceutical compositions may comprise a therapeutically effective 20 amount of a liposome composition alone or in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. Pharmaceutical compositions may comprise a therapeutically effective amount of one or 25 more liposome compositions in admixture with a pharmaceutically or physiologically acceptable

formulation agent selected for suitability with the mode of administration.

The pharmaceutical composition may contain formulation materials for modifying, maintaining or
5 preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as
10 glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen sulfite); buffers (such as borate, bicarbonate, Tris HCl, citrates, phosphates, other organic acids); bulking agents (such as mannitol or
15 glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta cyclodextrin or hydroxypropyl beta cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates
20 (such as glucose, mannose, or dextrans); proteins (such as serum albumin, gelatin or immunoglobulins); coloring; flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt forming counterions
25 (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal,

phenethyl alcohol, methylparaben, propylparaben,
chlorhexidine, sorbic acid or hydrogen peroxide);
solvents (such as glycerin, propylene glycol or
polyethylene glycol); sugar alcohols (such as mannitol or
5 sorbitol); suspending agents; surfactants or wetting
agents (such as pluronics, PEG, sorbitan esters,
polysorbates such as polysorbate 20, polysorbate 80,
triton, tromethamine, lecithin, cholesterol, tyloxapal);
stability enhancing agents (sucrose or sorbitol);
10 tonicity enhancing agents (such as alkali metal halides
(preferably sodium or potassium chloride, mannitol
sorbitol); delivery vehicles; diluents; excipients and/or
pharmaceutical adjuvants. (Remington's Pharmaceutical
Sciences, 18th Edition, A.R. Gennaro, ed., Mack
15 Publishing Company , 1990).

The pharmaceutical liposome compositions can
be selected for parenteral delivery. Alternatively, the
compositions may be selected for inhalation or for
delivery through the digestive tract, such as orally.
20 The preparation of such pharmaceutically acceptable
compositions is within the skill of the art.

In one embodiment, a pharmaceutical composition
may be formulated for inhalation. For example, a
liposome composition may be formulated as a dry powder
25 for inhalation. Pharmaceutical liposome composition
inhalation solutions may also be formulated with a

propellant for aerosol delivery. In yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT Application No. PCT/US94/001875, which describes pulmonary delivery
5 of chemically modified proteins.

It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention, liposome compositions which are administered in this fashion can
10 be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when
15 bioavailability is maximized and pre systemic degradation is minimized. Additional agents can be included to facilitate absorption of the liposome composition. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet
20 disintegrating agents, and binders may also be employed.

Another pharmaceutical composition may involve an effective quantity of liposome compositions in a mixture with non toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in
25 sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients

include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as
5 magnesium stearate, stearic acid, or talc.

Additional pharmaceutical liposome compositions will be evident to those skilled in the art, including formulations involving liposome compositions in sustained or controlled delivery formulations.
10 Techniques for formulating a variety of other sustained or controlled delivery means, such as liposome carriers, bio erodible microparticles or porous beads and depot injections, are also known to those skilled in the art.

The pharmaceutical liposome composition to be
15 used for in vivo administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method may be conducted either prior to or following lyophilization and
20 reconstitution. The composition for parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a
25 stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may
5 be stored either in a ready to use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

An effective amount of a pharmaceutical liposome composition to be employed therapeutically will
10 depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the liposome composition is being
15 used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.
20 A typical dosage may range from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to about 100 mg/kg.

25 The frequency of dosing will depend upon the pharmacokinetic parameters of the liposome composition

in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or
5 more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the
10 ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose response data.

The route of administration of the pharmaceutical composition is in accord with known
15 methods, e.g. orally, through injection by intravenous, intraperitoneal, intracerebral (intra parenchymal), intracerebroventricular, intramuscular, intra ocular, intraarterial, intraportal, or intralesional routes, by sustained release systems or by implantation devices.
20 Where desired, the compositions may be administered by bolus injection or continuously by infusion, or by implantation device.

Alternatively or additionally, the composition may be administered locally via implantation of a
25 membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or

encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed release bolus, or continuous
5 administration.

In some cases, it may be desirable to use pharmaceutical liposome compositions in an ex vivo manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to
10 pharmaceutical liposome compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In addition to the modes of administration enclosed herein, compositions of the invention can be
15 introduced for treatment into a mammal by other modes, such as but not limited to, intra-articular, intra-tumor, cerebrospinal, intra-arterial, intra-peritoneal, intra-rectal and colon, intra-lesion, topical, subconjunctival, intra-bladder, intra-vaginal, epidural, intracostal,
20 intra-dermal, inhalation, transdermal, trans-serosal, intra-buccal, oral, intra-nasal, intra-muscular, dissolution in the mouth or other body cavities, instillation to the airway, insufflation through the airway, injection into vessels, tumors, organ and the
25 like, and injection or deposition into cavities in the body of a mammal.

In addition to the treatment of other diseases or disorders disclosed herein, compositions of the invention can be used for the treatment of cerebrovascular ischemia, erectile dysfunction, female sexual arousal dysfunction, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, sepsis, septic shock, shock, adult respiratory distress syndrome, meconium aspiration, infantile respiratory distress syndrome, memory impairments, dementia, cognitive disorder, autism, central nervous system disease (such as Parkinson's disease, Alzheimer's disease), migraine, cerebral palsy, neurodegenerative diseases, stroke, hypertension, pulmonary hypertension, portal hypertension, ischemic heart disease, arthritis, osteoarthritis, gouty arthritis, crystal-induced arthritis, snoring, arteritis, rhinitis, psoriasis, radiation-induced tissue injury, septicemia, exocrine pancreatic insufficiency, pancreatitis, spondyloarthropathies, hypersensitivity, anaphylaxis, encephalopathy, vascular insufficiency, tetanus, tenosynovitis, synovitis, ischemia, neuritis, nerve palsy, pressure ulcers, progressive multifocal leukoencephalopathy, meningitis, pericarditis, myocarditis, inflammation, multiple sclerosis, multiple organ system failure, nephritis, obliterative bronchiolitis, bronchiolitis obliterans-organizing

pneumonia, encephalitis, diversion colitis and pouchitis, inflammatory polyps, polymyositis, polychondritis, polyarthrititis, pemphigus, bullous pemphigoid, acne, rosacea, nephritis, glomerulonephritis, cancer, 5 interstitial lung disease, idiopathic pulmonary fibrosis, sarcoidosis, tuberous sclerosis, vasculitis, toxic shock syndrome, asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, bronchiectasis, acute coronary syndrome, angina pectoris, gastroparesis, mental 10 retardation, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, muscle disease, autoimmune diseases (such as lupus erythematosus, scleroderma, dermatomyositis, Sjogren's syndrome, CREST), Raynaud's phenomenon, Bierger's 15 disease, peripheral vascular disease, chronic venous ulcers, dermatitis, diabetes mellitus, atherosclerosis, myocardial infarction, gastric and duodenal ulcers, ischemic heart disease, fibrosis, restenosis, thrombosis, cardiac failure, cardiomyopathy, encephalopathy, 20 cerebritis, ankylosing spondylitis, osteoarthritis, renal failure, neuritis, neuropathy, spondylosis, retinal disease, prevention of neuronal cell death in a mammal, food impaction, VIPoma, wound healing, constipation, arthropathy, pre-eclampsia, burns, skin ulcers, toxic 25 megacolon, organ, tissue and cell preservation, Reiter's

syndrome, psoriatic arthritis, prevention of hypotension and hypertension evoked by said peptides.

The following examples are intended for illustration purposes only, and should not be construed
5 as limiting the scope of the invention in any way.

The present invention is further illustrated by way of the following examples. Example 1 is a comparative example describing the state of the art which illustrates that incorporation of a bioactive VIP peptide
10 into liposomes increases the duration and magnitude of the peptide activity when administered to hamsters with spontaneous hypertension. Example 2 relates to an examination of the same biologically active peptide in association with a sterically stabilized liposome (SSL)
15 according to the methods of invention but in which the liposome provides an even more dramatic increase in peptide activity. Example 3 provides an alternative method for preparing an SSL according to the invention wherein differing preparative techniques are shown to
20 result in vastly different levels of peptide activity. Example 4 provides an analysis of morphological features in liposomes prepared by the methods described in Example 3. Example 5 relates to a modified method for producing SSL with a bioactive peptide wherein simplification of
25 the preparative process does not affect peptide activity *in vivo*. Example 6 describes manufacture and use of

diagnostic liposome products for use in acoustic
reflective imaging based on echo-reflective properties of
the liposomes. Example 7 relates to the ability of
DSPE-PEG5000 to interact with and stabilize interleukin-2
5 (IL-2) in aqueous medium. Example 8 provides an analysis
of the physiochemical properties of sterically stabilized
micelles prepared with distearoyl-
phosphatidylethanolamine (DSPE) conjugated to different
molecular weight (2000, 3000, 5000) PEG. Example 9
10 studied DSPE conjugated with 1, 2, 3 or 5 kDa PEG in
solution, alone or mixed with EYPC by static and dynamic
light scattering. Example 10 addresses the issue of
covalent conjugation of VIP to SSL and provides an
analysis of the targeting ability of VIP-SSL to tumors
15 using MNU-induced rat breast cancer tissues.

Example 1

Bioactivity of Peptides in Conventional Liposomes (Comparative Example)

According to this example, prior art methods
20 for incorporation of VIP into liposomes were reproduced
in order to provide a basis for comparison of the methods
of the invention. Because previous observations have
suggested that VIP plays a role in regulating vasomotor
tone, it was first decided to examine VIP activity in
25 *situ* on peripheral microcirculation as a function of the
vehicle used to dissolve and deliver the peptide. More
specifically, a first examination was carried out to

determine whether topical administration of VIP could elicit vasodilation in peripheral microcirculation of hamsters with spontaneous hypertension and whether encapsulation of VIP into conventional unilamellar liposomes could modulate any observed response.

Adult male hamsters with spontaneous hypertension (n = 21) and age- and genetically-matched normotensive controls (n = 20) were purchased from the Canadian Hybrid Farms, Halls Harbor, NS, Canada. In preparation, the animals were anesthetized interperitoneally with sodium pentobarbital (6 mg/100 g body weight) and a tracheostomy was performed to facilitate spontaneous breathing. The left femoral vein was cannulated to inject supplemental anesthesia (2 to 4 mg per 100 g body weight per hour) during the experiment. A catheter was inserted into the left femoral artery to record systemic arterial pressure and heart rate. Body temperature was monitored to maintain a constant 37-38°C throughout the experiment using a heating pad.

In order to visualize microcirculation of the cheek pouch, previously described methods were employed [Gao, et al., *Life Sci.* 64: PL274-PL252 (1994); Mayhan and Joyner, *Microvasc. Res.* 28: 159-179 (1984); Mayban and Rubinstein, *Biochem. Biophys. Res. Commun.* 184:1372-1377 (1992); Raud, *Acta Physiol. Scand. Suppl.* 578:1-58 (1989); Rubinstein and Mayhan, *J. Lab. Clin. Med.*

125:313-318 (1995); Rubinstein, et al., *Am. J. Physiol.* 261 (*Heart Circ. Physiol.* 30):111913-111918 (1991); and Suzuki, et al., *Life Sci.* 57:1451-1457 (1995)]. Briefly, the left cheek pouch was spread over a small plastic baseplate, and an incision was made in the outer skin to expose the cheek pouch membrane. The avascular connective tissue layer was removed, and a plastic chamber was positioned over the baseplate and secured in place by suturing the skin around the upper chamber. This arrangement formed a triple-layered complex: the baseplate, the upper chamber, and the cheek pouch membrane exposed between the two plates. The upper chamber was connected to a reservoir containing warmed bicarbonate buffer (37-38°C) that allowed continuous suffusion of the cheek pouch. The buffer was bubbled continuously with 95% N₂ - 5% CO₂ (pH 7.4). The chamber was also connected via a three-way valve to an infusion pump (Sage Instruments, Cambridge, MA) that allowed controlled administration of drugs into the suffusate. This method of animal preparation was similarly utilized in later investigations as indicated below.

Liposomes containing VIP were prepared according to the methods of Gao, et al., *Life Sci.* 64: PL274-PL252 (1994); Gregoriadis and Florence, *Drugs* 45:15-28 (1993); MacDonald, et al., *Biochem. Biophys. Acta* 1061:297-303 (1991); and Suzuki, et al., *Life Sci.*

57:1451-1457 (1995). Briefly, a lipid composition consisting of egg yolk phosphatidylcholine (Sigma, St. Louis, MO), egg yolk phosphatidylglycerol (Sigma), and cholesterol (Sigma) at a 4:1:5 molar ratio (total phospholipid content, 5 mg) was mixed in chloroform (Sigma) and the solvent evaporated to dryness. The dried lipid film was resuspended in 100 µl 0.15 M NaCl solution containing 0.7 mg VIP by vortex mixing and sonication. The suspension was subjected to five cycles of freeze-thawing using a dry ice-ethanol bath and extruded nine times through two polycarbonate filters (pore size 3 µm; Nuclepore, Pleasanton, CA) using a LiposoFast apparatus (capacity of syringe, 0.5 ml; Avestin, Ottawa, ON, Canada). Liposomes were collected using a disposable gel filtration column (Econo-pac 10DG, polyacrylamide gel, 10 ml bed vol.) in 0.15 N NaCl [MacDonald, et al., *Biochim. Biophys. Acta* 1061:297-303 (1991)]; the liposome fraction was recovered in the void volume and stored at 4°C until use.

Change in arteriolar diameter was determined as follows. Microcirculation in the cheek pouch was epilluminated with a fiber-optic light source and observed through a Nikon microscope. The image was projected through the microscope and into a closed-circuit television system that consisted of low-light television camera, television monitor, and videotape recorder

(Panasonic, Yokohama, Japan). The inner wall diameter of second-order arterioles in the cheek pouch was measured from the video display of the microscope image using a videomicrometer (VIA-100, Boeckeler Instruments, Tucson, AZ). Calibration of the magnification of the video system was carried out with a microscope stage micrometer to give microvascular dimensions in micrometers. Vessels were chosen for observation on the basis of clarity on the monitor screen and location within the arteriolar branching pattern in the cheek pouch. In each animal, the same arteriolar segment was used to measure changes in inner wall luminal diameter during the experiment. In some studies, animals were used in more than one treatment group once measures of arteriolar diameter from previous interventions returned to baseline.

VIP alone or encapsulated in liposomes was suffused for 7 minutes at a concentration of VIP of either 0.05 or 0.1 nmol peptide, and more than 30 minutes elapsed between subsequent applications of the peptide. Changes in arteriolar diameter before, during, and after topical application of VIP were determined as outlined above. The concentrations of VIP used in these experiments were based on previous studies [Gao, et al., *Life Sci.* 64: PL274-PL252 (1994); Suzuki, et al., *Life Sci.* 57:1451-1457 (1995)].

Results indicated that suffusion of VIP alone at both concentrations was associated with significant vasodilation in normotensive hamsters with the maximal response observed within 4 minutes of the start of suffusion. Arteriolar diameter returned to baseline within 1 minute after suffusion of VIP was stopped. In contrast, suffusion of VIP alone had no significant effects on arteriolar diameter in hamsters with spontaneous hypertension. This blunted response to VIP in hypertensive animals could not be attributed to nonspecific damage to the endothelium because nitroglycerin, an endothelium independent vasodilator in the cheek pouch [Mayban and Rubinstein, *Biochem. Biophys. Res. Commun.* 184:1372-1377 (1992); Rubinstein, et al., *Am. J. Physiol.* 261 (Heart Circ. Physiol. 30):111913-111918 (1991)] elicited vasorelaxation of similar magnitude in both groups.

With suffusion of VIP at the same amounts but encapsulated in liposomes, normotensive animals showed significant, concentration-dependent potentiation and prolongation of vasorelaxant effects in comparison with VIP alone. The maximal response was detected 3 to 4 minutes after suffusion began and significant vasodilation persisted almost 9 minutes after suffusion was stopped. In hamsters with spontaneous hypertension, liposome encapsulated VIP produced a significant

vasorelaxant effect of magnitude similar to that observed in the normotensive animals. A maximal effect was detected within 4 minutes from the start of suffusion and significant vasodilation persisted over 3 minutes after suffusion was stopped. Even though encapsulation of VIP in liposomes was able to restore vasorelaxant effects of the peptide in hamsters with spontaneous hypertension to a magnitude similar to that observed in normotensive animals, the duration of effect was significantly shorter.

These results suggested that vasodilation elicited by VIP in peripheral microcirculation of normotensive hamsters is composed of two components; the first regulating the magnitude of the response and the second its duration. While the former was expressed in both aqueous and lipid environments, the latter was observed only when VIP was partitioned into lipid bilayers [Gao, et al., *Life Sci.* 64: PL274-PL252 (1994); Gregoriadis and Florence, *Drugs* 45:15-28 (1993); MacDonald, et al., *Biochim. Biophys. Acta* 1061:297-303 (1991); Musso, et al., *Biochemistry* 27: 8174-8181 (1988); Noda, et al., *Biochim. Biophys. Acta* 1191: 324-330 (1994); Robinson, et al., *Biopolymers* 21:1217-1228 (1982); Soloviev, et al., *J. Hypertens.* 11:623-627 (1993); Suzuki, et al., *Life Sci.* 57:1451-1457 (1995)] which may provide an appropriate environment for α -helix

formation in VIP molecules [Noda, et al., *Biochim. Biophys. Acta* 1191: 324-330 (1994); Robinson, et al., *Biopolymers* 21:1217-1228 (1982)]. For reasons that are not entirely clear, the lipid-dependent component of VIP-induced vasodilation in peripheral microcirculation was found to be absent in hamsters with essential hypertension.

Example 2

**Characterization of Bioactivity
in Sterically Stabilized Liposomes**
Having demonstrated that VIP encapsulation in conventional liposomes restored capacity of the peptide to induce vasodilation in hamsters with spontaneous hypertension, changes in VIP activity when associated with the sterically stabilized liposomes of the invention were examined.

Normotensive animals were prepared essentially as described in Example 1 with the following changes. Adult male golden Syrian hamsters (n=28; 120-140 g body weight) were anesthetized with pentobarbital sodium (6 mg/100 g body weight, i.p.) and a femoral vein was cannulated to administer the intravascular tracer, fluorescein isothiocyanate labeled dextran (FITC-dextran dissolved in 1.0 ml saline; molecular mass 70 kDa; 40 mg/100 g body weight and administered over 1 minute) and supplemental anesthesia (2-4 mg/100 g body weight/hour). To visualize changes on microcirculation of the cheek

pouch, the procedure described above in Example 1 was employed.

Sterically stabilized liposomes (SSL) were prepared as follows. Egg yolk phosphatidylcholine (Sigma), egg yolk phosphatidylglycerol (Sigma), cholesterol (Sigma) and polyethylene glycol (molecular mass, 1,900) linked to distearoyl-phosphatidylethanolamine (molar ratio, 5:1:3.5:0.5; phospholipid content, 17 mmol) were dissolved and mixed in chloroform [Gao, et al., *Life Sci.* 54: PL247-PL252 (1994); Lasic and Martin. Stealth Liposomes, CRC Press, Inc.:Boca Raton, Florida, 1995; Suzuki, et al., *Am. J. Physiol.* 271:H282-H287 (1996)]. The solvent was evaporated at 45°C in a rotary evaporator under vacuum overnight. The resulting lipid film was rehydrated in 250 ml saline, vortexed, bath-sonicated for 5 minutes, and extruded through stacked polycarbonate filters using the LiposoFast apparatus (consecutive pore sizes: 200, 100, 50 nm; AVESTIN, Inc., Ottawa, ON, Canada). Human VIP (0.4 mg) and trehalose (30 mg), a cryoprotectant, were added to the extruded suspension, which was then frozen in acetone-dry ice bath and lyophilized overnight at -46°C under constant pressure (Foreseen 6, Labconco, Kansas City, MO). Thereafter, the lyophilized "cake" was resuspended in 250 ml deionized water. VIP associated with SSL was separated from free VIP by column

chromatography (Bio-Gel A-5m, Bio-Rad Laboratories, Richmond, CA) and stored at 4°C for a maximum of 15 days. The size of SSL was 250 ± 50 nm as determined by quasi elastic light scattering (Nicom model 270 submicron particle sizer, Pacific Scientific, Menlo Park, CA). The phospholipid concentration in SSL was determined by the Barlett inorganic phosphate assay [Kates, M. Techniques in Lipidology, Work and Work (Eds.) Elsevier:New York, New York (1972) pp. 354-356]. VIP concentration in SSL was determined by a commercially-available ELISA assay kit (Peninsula Laboratories, Belmont, CA) after dissolving SSL with sodium dodecyl sulfate 1%. The recovery was 30% for VIP and 50% for phospholipids, giving a ratio of 0.004 mole VIP/mole of phospholipids.

Determination of arteriolar diameter was carried out as described above in Example 1. In a first group of animals, 0.42 and 0.85 nmol VIP in SSL were suffused for 1 hour in an arbitrary order. At least 45 minutes elapsed between subsequent suffusions of VIP in SSL [Suzuki, et al., *Life Sci.* 57:1451-1457 (1995); Suzuki, et al., *Am. J. Physiol.* 271:H282-H287 (1996)]. Arteriolar diameter was measured immediately before suffusion, every minute during suffusion of VIP in SSL and at 5 minute intervals thereafter. Previous observations indicated that suffusion of saline alone for the entire duration of the experiment was associated with

no significant change in arteriolar diameter. In another group of animals, VIP in SSL (0.1 nmol) or empty SSL at a concentration equivalent to that in 0.1 nmol VIP in SSL (18 nmol/ml phospholipids) were suffused for 7 minutes.

5 Suffusion of animals in the first group with 0.42 nmol and 0.85 nmol VIP in SSL for 1 hour produced a significant, concentration dependent, and prolonged increase in arteriolar diameter. Significant vasodilation was observed within 2 minutes of the start
10 of suffusion which maximal within 5 minutes of the beginning of suffusion. Arteriolar diameter returned to baseline levels 50 minutes after suffusion of VIP in SSL was stopped. Suffusion with empty SSL for 1 hour had no significant effect on arteriolar diameter.

15 Suffusion of normotensive animals in the second group with 0.1 nmol VIP in SSL also elicited a significant increase in arteriolar diameter from baseline but to a lessor extent than that observed in first group. Arteriolar diameter returned to baseline 13 minutes after
20 suffusion of VIP in SSL was stopped. Suffusion of empty SSL had no significant effects on arteriolar diameter. Even though vasodilation for 1 hour was greater than that observed for 7 minute suffusion, the results indicated that using 0.1 nmol peptide would still produce a
25 significant change over baseline.

In order to determine whether the vasodilating effects of VIP in SSL were caused in part by non-specific damage to microvessels resulting in macromolecular efflux from the cheek pouch [Gao, et al., *Life Sci.* 54: PL247-PL252 (1994); Raud, *Acta Physiol. Scand. Suppl.* 578:1-58 (1989)], two indices were used to determine clearance of macromolecules from the cheek pouch under control and experimental conditions as previously described [Gao, et al., *Life Sci.* 54: PL247-PL252 (1994); Raud, *Acta Physiol. Scand. Suppl.* 578:1-58 (1989)]. The first was a determination of the number of fluorescent "spots" or leaky sites around postcapillary venules and the second was a determination of FITC-dextran clearance from the cheek pouch.

After suffusing animals with bicarbonate buffer for a 30 minute equilibration period, FITC-dextran was administered intravenously. VIP in SSL (0.1 nmol) was then suffused for 7 minutes and the number of leaky sites was determined initially every minute for 7 minutes, and then at 5 minute intervals for 60 minutes thereafter. Clearance of FITC-dextran was determined before suffusion of VIP in SSL and every 5 minutes during and after suffusion for 60 minutes [Gao, et al., *Life Sci.* 54: PL247-PL252 (1994)].

Results indicated that suffusion of nmol VIP in SSL was not associated with visible leaky site formation.

Likewise, clearance of FITC-dextran during suffusion of saline was essentially identical to clearance during suffusion of VIP in SSL.

Combined these results indicated that suffusion
5 of VIP in SSL onto hamster cheek pouch elicits significant and prolonged concentration-dependent vasodilation. This response was not related to non-specific damage to microvascular endothelium because arteriolar diameter returned to baseline once suffusion
10 of VIP in SSL was stopped and because VIP in SSL did not elicit macromolecular efflux from post-capillary venules in the cheek pouch. These results suggested that VIP in SSL could be useful in restoring vascular reactivity in the peripheral microcirculation in certain diseases where
15 endothelium-dependent vasodilation is impaired, such as hypertension, congestive heart failure, diabetes mellitus and impotence [Paul and Ebadi, *Neurochem. Int.* 23:197-214 (1993); Suzuki, et al., *Am. J. Physiol.* 271:H282-H287 (1996)].

20

Example 3

Comparison of Bioactivity as a Function of Liposome Preparation

Having demonstrated that VIP in SSL exhibits enhanced bioactivity over VIP preparations in
25 conventional liposomes, alternative methods of preparation were examined in order to determine optimal

compositions, methods of their preparation, and to further characterize the bioactivity of VIP in SSL.

Two different methods of liposome preparation methods were utilized. In both, the lipids distearoyl-
5 phosphatidylethanolamine (PEG-DSPE) (Sequus Pharmaceuticals, Menlo Park, CA), Egg yolk phosphatidylcholine (PC) (Sigma Chemical Co., St. Louis, MO), and egg yolk phosphatidylglycerol (PG) (Sigma Chemical Co., St. Louis, MO), were combined with
10 cholesterol (Sigma Chemical Co., St. Louis, MO) at a PEG-DSPE:PC:PG:Chol molar ratio of 0.5:5:1:3.5. Total phospholipid content of the mixture was 17 pmol. The mixture was mixed in chloroform in a round bottom flask, the solvent evaporated at 45°C in a rotary evaporator
15 (Labconco, Kansas City, MO) and the mixture desiccated under vacuum overnight.

In a first method of preparation (not contemplated by the invention), VIP was initially mixed with a lipid composition followed by extrusion and
20 repeated freezing and thawing to produce liposomes. Briefly, the dry lipid film was rehydrated with 250 µl 0.15 M saline (0.9% w/w NaCl) containing 0.4 mg VIP (American Peptide Co., Sunnyvale, CA). The mixture was vortexed, sonicated for 5 minutes in a 175.5W water bath
25 sonicator (Fisher Scientific, Itasca, IL), and freeze-thawed five times in an acetone-dry ice bath. The

suspension was extruded through polycarbonate filters using the Liposofast apparatus (pore size 200 nm, AVESTIN, Inc., Ottawa, ON, Canada). The liposome-associated VIP was separated from the free VIP by column chromatography (BioGel A-5m, Bio-Rad Laboratories, Richmond, CA) and stored at 4°C until use. Column elution was carried out using the 15 M saline solution described above. Vesicle size was determined by quasi elastic light scattering [Alkan-Onyuksel, et al., *J. Pharm. Sci.* In press (1996)] with a Nicomp 270 particle sizer (Particle Sizing Systems, Santa Barbara, CA) and liposomes prepared by this method were found to have an average mean diameter of 224 ± 36 nm.

In a second method of preparation which is contemplated by the invention, a lipid mixture was first extruded, after which VIP was mixed with the formed liposomes. Briefly, a dry lipid film prepared as before was rehydrated with 250 ml 0.15 M saline without VIP. The mixture was vortexed, bath-sonicated for 5 minutes, and extruded through stacked polycarbonate filters of 200, 100, and 50 nm pore size to give a vesicle size of about 80 nm. VIP (0.4 mg) and trehalose (30 mg) (Sigma Chemical Co., St. Louis, MO) as a cryoprotectant were added in powder form to the extruded suspension. The mixture was incubated either at room temperature for two hours or overnight at 4°C, frozen in an acetone-dry ice

bath, and lyophilized at -46°C under a pressure of approximately 5×10^{-3} MBar overnight (Labconco "Freezone 6", Kansas City, MO). The lyophilized "cake" was resuspended with 250 μl deionized water. During freeze-drying, VIP and phospholipid bilayers were in close contact which provides a promotes passive drug loading. Column separation and storage conditions were the same as above. Liposomes prepared by this method were found to have an average diameter of 250 ± 50 nm by the method described above, suggesting that freeze-drying permitted vesicle fusion. VIP concentration in the liposomes was determined after treatment with sodium dodecyl sulfate 1% by a VIP ELISA assay kit (Peninsula Laboratories, Belmont, CA) and the phospholipid concentration was evaluated by the Barlett inorganic phosphate assay [M. Kates. *Techniques in Lipidology*, Work and Work (Eds), Elsevier, New York (1972) pp. 354-356]. For both methods of preparation, approximately 30% of the starting VIP was found to be liposome associated and approximately 50% of the starting phospholipids was recovered giving a ratio of approximately 0.004 mole VIP/mole of phospholipid.

Two types of *in vivo* experiments were performed to determine the vasorelaxant and hypotensive effects of VIP in liposomes prepared by the two methods. In a first series of experiments, the bioactivity of VIP in the liposome preparations was examined as a function of

vasodilation, while in the second series of experiments, the duration and efficacy of VIP in the two liposome preparations on mean arterial pressure was measured.

In the first experiments, the bioactivity of
5 VIP in the liposome preparations was measured as a function of change in arteriolar diameter in hamster cheek pouch. Adult male golden Syrian hamsters (n = 9) (Sasco, Omaha, NE) were prepared as previously described [Suzuki, et al., *Life Sci.* 57(15):1451-1457 (1995);
10 Suzuki, et al., *Am. J. Physiol.* 271:11282-H287 (1996); Suzuki, et al., *Am. J. Physiol.* In press (1996)] and anesthetized with pentobarbital sodium (2-4 mg/100 g body weight) via a cannulated femoral vein. A femoral artery was cannulated to record systemic arterial pressure and
15 heart rate using a transducer and a strip-chart recorder (Model 260, Gould Instrument Systems Inc., Valley View, OH). The visualization of the microcirculation of the cheek pouch, an established animal model to investigate the vasoactive effects of neuropeptides *in situ*, was
20 conducted as previously described [Suzuki, et al., *Life Sci.* 57(15):1451-1457 (1995); Suzuki, et al., *Am. J. Physiol.* 271:11282-H287 (1996); Suzuki, et al., *Am. J. Physiol.* In press (1996)]. The inner-wall diameter of second order arterioles in the hamster cheek pouch was
25 measured from the video display of the microscope image using a videomicrometer (VIA 100; Boeckeler Instruments,

Tucson, AZ). In each animal, the same arteriolar segment was used to measure changes in diameter during the experiment. The hamster cheek pouch was first suffused with bicarbonate buffer during a 30 minutes equilibration
5 period, and then with 1.4 ml of each liposome preparations described above for 7 minute.

VIP in liposomes prepared by the first method, outside the scope of the invention, did not elicit an increase in arteriolar diameter significantly different
10 from previously reported observations with 0.1 nmol VIP dissolved in saline, i.e. approximately 10% [Suzuki, et al., *Life Sci.* 57(15):1451-1457 (1995)]. When this observation is compared to the previous observation that VIP in conventional liposomes prepared with the same
15 method but without an extrusion step shown enhanced and prolonged effects *in situ* [Suzuki, et al., *Life Sci.* 57(15):1451-1457 (1995)], three possibilities are suggested to account for the loss of activity of VIP in SSL prepared by the present method; the extrusion
20 process, the lipid composition or the smaller size of the vesicles. Regardless of the reason than SSL prepared by this method did elicit an enhanced or prolonged effect on arteriolar diameter, this result is significant in demonstrating that SSL in general are not amenable to the
25 present invention. VIP (0.1 nmol) in liposomes prepared by the second method and within the scope of the

invention, elicited a significant increase in arteriolar diameter from baseline values and the increase persisted for 9 to 16 minutes after suffusion was stopped. This result was more similar to previous observations using
5 conventional liposomes [Suzuki, et al., *Life Sci.* 57(15):1451-1457 (1995)].

In examining the duration and efficacy of VIP in the two liposome preparations on mean arterial pressure, the following procedure was carried out. Adult
10 mate hamsters with spontaneous hypertension (n = 12) were obtained from the Canadian Hybrid Farms (Hall Harbour, Nova Scotia, Canada). Approximately 500 µl each of three test preparations, liposomes prepared by the second method above, VIP in aqueous solution, and liposomes
15 without VIP, were injected administered over the course of 1 minute in the femoral vein. Continuous anesthesia of the animals limited the duration of the experiment to 6 hours.

After injection of 0.1 nmol liposome-associated
20 VIP, a significant and gradual decrease in mean arterial pressure up to 50% was observed in the first 2.5 hours which persisted for the 6 hour observation period of the experiment as shown in Figure 6. No significant effect on mean arterial pressure was observed using empty
25 liposomes or VIP in aqueous solution. These data suggest that intravenously administered VIP in SSL successfully

normalized the mean arterial pressure of hamsters with spontaneous hypertension for at least 6 hours.

Interestingly, the dose required to produce normal blood pressure was very low compared to previous observations wherein the same amount of VIP in conventional liposomes produced a 30% decrease in mean arterial pressure of normotensive hamsters [Gao, et al., *Life Sci.* 54:PL247PL252 (1994)], but this observation may be attributed to a higher sensitivity of hamsters with spontaneous hypertension to VIP.

Since SSL having the same composition and size prepared by the method of the invention (i.e., the second method) retained the VIP activity, the results suggest that extrusion was responsible for the loss of bioactivity in the first liposome preparation. This possibility is consistent with a previous demonstration wherein interleukin-2 was shown to lose more than 25% activity after extrusion [Kedar, et al., *J Immunother.* 16:47-59 (1994)], but inconsistent with an observation that vasopressin was not significantly affected by extrusion [Woodle, et al., *Pharm Res.* 9(2):260-265 (1992)].

Example 4

Morphological Evaluation of SSL

For morphological evaluation of vesicle prepared by both methods described in Example 3, liposomes were prepared for freeze-fracture according to

standard techniques as reported previously [Alkan-Onyuksel, et al., *J. Pharm. Sci.* In press (1996)].

Briefly, drops of each liposome suspension were frozen in liquid-nitrogen cooled Freon 22, fractured using a
5 Balzers BAF 301 freeze-etch unit at -115°C, and coated with platinum and carbon. The replicas were cleansed in a minimum of two changes of sodium hypochlorite, washed with distilled water, dried, collected on 200 mesh copper grids, examined and photographed with a JEOL 100CX
10 transmission electron microscope at 80kv.

Examination of SSL prepared by the method of the invention revealed multivesicular vesicles, suggesting that freeze-drying caused some fusion of the small pre-extruded SSL to form vesicle in a vesicle
15 structures, consistent with the observed increase in mean diameter from 80 nm to 250 nm. This observation is consistent with previously reported fusion events during the freeze-drying/reconstitution process of SSL. [Szucs and Tilcock, *Nucl. Med. Biol.* 22:263-268 (1995)].
20 Possibly, the formation of larger vesicles may have promoted the entrapment of VIP molecules inside the final liposomes, while retaining a rather small mean size and distribution required for long circulation times.

Example 5

25 **Peptide Activity in a Simplified Liposome Preparation**
According to this example a simple method for producing SSL associated with a biologically active

peptide is provided which acts to maintain the resulting liposomes at a size approximately less than 200 nm. In addition an alternative method of preparation was examined and the effects of the preparative method on peptide activity determined.

Egg yolk PC, egg yolk PG, cholesterol, and PEG-DSPE were mixed in chloroform at a molar ratio of 5:1:3.5:0.5 and the solvent evaporated using a water bath at 45°C. The lipid film was dried overnight and resuspended in 250 µl saline. The mixture was vortexed, sonicated for 5 minutes and extruded through stacked polycarbonate filters using a LiposoFast apparatus. Human VIP was added to the resulting liposomes having an average diameter of less than 300 nm and the mixture incubated overnight at 4°C. Free VIP was separated from the VIP-associated liposomes using a Bio-gel A-5m column and collected liposomes stored under argon at 4°C until use. Size of the liposomes determined by quasi electric light scattering indicated an average diameter of 162 ± 59 nm. Phospholipid concentration and VIP recovery were determined as described above and found to be 44% for VIP and 50% for phospholipid, giving a VIP:phospholipid molar ratio of 0.006.

Adult male golden Syrian hypertensive hamsters were prepared for intravital microscopy, cheek pouch microcirculation observed and measured, and mean arterial

pressure determined, each technique as described above. Measurements were made with administration of VIP in aqueous solution, VIP in SSL as prepared above, and SSL in the absence of VIP.

5 Suffusion of VIP in SSL for 7 minutes was associated with a significant, concentration dependent and prolonged increase in arteriolar diameter. Significant vasodilation was observed within 1 minute from the start of suffusion and was maximal within the first 5 minutes. Arteriolar diameter returned to normal levels within 8 minutes after suffusion was stopped. VIP in aqueous solution and empty SSL has no effects.

VIP in SSL also elicited a significant reduction in mean arterial pressure with the maximal effect observed within 30 minutes from the onset of suffusion. Blood pressure remained low during the entire course of the 6 hour observation period. As before, VIP in aqueous solution and empty SSL had no effect.

These results indicated that the dehydration/rehydration step described in Example 3 is not necessary to formation of active liposome preparations. More importantly, liposomes prepared by this method retained an average diameter of less than 200 nm and retained equal, if not higher, VIP activity than either liposome preparation described in Example 3. As an additional advantage, the VIP:phospholipid ratio which

resulted from this preparative method was higher (0.006 vs. 0.004) when compared to the method of Example 3.

Example 6

SSL in Acoustic Reflectivity Assays

5 SSL including VIP were prepared and utilized for imaging using acoustic reflectivity measurements as follows.

 Liposomes prepared as described in Example 3 were transferred to liquid scintillation vials and imaged
10 with a 20 MHz high-frequency intravascular ultrasound (IVUS) imaging catheter (Boston Scientific Inc., Sunnyvale, CA). The IVUS catheter was passed through the vial cap and secured. Instrument settings for gain, zoom, compression, and rejection levels were optimized at
15 the initiation of the experiment and held constant for all samples. Images were recorded onto ½ inch VHS videotape in real time for subsequent playback and image analysis.

 Relative echogenicity (apparent brightness) of
20 liposome formulations was objectively assessed by computer-assisted videodensitometry. The process involved acquisition, pre-processing, automated liposome identification, and gray scale quantification. Image processing and analysis were performed with Image Pro
25 Plus Software (Ver. 1.0, Media Cybernetics, Silver Springs, MD) running on a dedicated computer (486 CPU, 66 MHz). Randomly selected IVUS images were acquired from

video tape for each liposome formulation. Images were digitized to 640 x 480 pixels spatial resolution (approximately 0.045 mm/pixel) and 8 bit (256 levels) amplitude resolution. all analyzed IVUS data were collected at a fixed instrument gain level. The distribution of gray scale values within the image was then adjusted to cover the entire range of possible gray levels using a linear transformation algorithm (i.e., dynamic range was maximized). Image brightness was subjectively scaled such that a reference feature, common to each image, retained a constant gray scale value over all images. An automated-liposome detection routine was then run to identify liposomes suspended in solution within an annular region of interest set at a constant radial distance from the imaging catheter. The automated liposome detection routine identified all "bright" objects within the analysis annulus having a gray scale level greater than 29, a roundness ratio (i.e., ratio of maximum diameter:minimum diameter) less than 2.5, and a size greater than 4 pixels. This procedure excluded virtually all imaging artifacts from the detection algorithm. Thus, object identified were considered to be "liposomes." Each liposome was outlined and numbered by the computer program. The average gray scale and size of each value of all pixels identified as "liposomes" with a given image was then computed and used to characterize

the echogenicity of a given liposome formulation. The results of these experiments demonstrate that the acoustic reflectance of the VIP liposome preparation has a gray scale of 119 (on a gray scale of 0 to 255 with 255 as pure white and 0 as pure black). Larger liposomes produced using lyophilization methods described in PCT Publication WO 93/20802 are characterized by an acoustic reflectance of about 110-120 while liposomes comprising contrast media such as Albunex® have an acoustic reflectance of about 110-120. Accordingly, the invention provides small diameter liposomes while retaining their acoustic imaging properties.

Example 7

DSPE-PEG 5000 Increases Physical Stability of Human Interleukin-2 In Vitro

According to this example, the ability of DSPE-PEG 5000 to interact with and stabilize IL-2 in aqueous medium was assessed. Protein stability was determined by circular dichroism and fluorescence spectroscopy for secondary and tertiary structure determinations, respectively, turbidity by UV, and visual testing.

IL-2 is a well characterized hydrophobic protein containing a single tryptophan within a four α -helical bundle. These properties render IL-2 ideal for interacting with phospholipids and characterization by fluorescence spectroscopy in that the tertiary structure may be monitored by a shift in the emission wavelength.

The isoelectric point (pI) of IL-2 is 7.05. At this pH the protein is chemically most stable but physically least stable. IL-2 was stored in the presence of DSPE-PEG 5000 at the pI of the cytokine so that the protein
5 would be unfolded and electrically neutral to provide a physically interactive environment.

In order to determine the ability of DSPE-PEG 5000 to interact with and stabilize IL-2 in aqueous medium samples were prepared as follows. To obtain the
10 protein in the native state, pure lyophilized recombinant human IL-2 (no excipients) was dissolved in 15mM sodium acetate at pH 5.0. DSPE-PEG 5000 micelles (100 μ M) were prepared by adding 100 mM Tris buffer at pH 7.1; to dry DSPE-PEG 5000. The phospholipid mixture was vortexed for
15 2 minutes and then sonicated under vacuum for 5 minutes. Micellar size (~25nm) was assessed in a Nicomp 380 Particle Size Analyzer prior to the addition of protein. Protein was added to the micellar solution or to Tris buffer alone. The final concentration of IL-2 in all
20 protein samples was 0.12 mg/ml. DSPE-PEG 5000 was 70 μ M in all DSPE-PEG 5000 samples. Final pH of the solution was between 7.0 and 7.1. DSPE-PEG 5000 in buffer and buffer alone were included as controls. Samples were stored in type I, glass vials with FluoroTec®
25 coated stoppers and stored at 5°C and 25°C for 28 days. Experiments were carried out in duplicate.

Sample analysis was conducted by circular dichroism (CD) for changes in secondary structure, fluorescence spectroscopy (excitation 295 nm, emission 305-500nm) for changes in tertiary structure, UV (A360) for turbidity, and visual appearance (color, clarity and precipitate). CD spectra were analyzed by SELCON (Softsec version 1.2, 1996) to determine % α -helical content.

Visual turbidity was noted upon initial reconstitution of the lyophilized protein. However, the turbidity observed in the protein solution decreased upon addition into DSPE-PEG 5000 as compared to similar dilution with buffer alone. 100 μ M DSPE-PEG 5000 micelles in 100mM Tris buffer (pH 7.1) yielded a clear, colorless solution. The turbidity observed in the IL-2/DSPE-PEG 5000 samples at 25°C increased at the same rate as that observed in the DSPE-PEG 5000/buffer samples, suggesting that the increased turbidity was caused primarily by degradation of DSPE-PEG 5000. IL-2/DSPE-PEG 5000 samples stored at 5°C remained unchanged over the 28-day period studied.

Secondary structure of IL-2 was preserved in the presence of DSPE-PEG 5000 for the entire study whereas IL-2 in buffer alone retained <50% of the original α -helical structure after 7 days in solution regardless of storage temperature. No peak shift in

fluorescence was observed between IL-2/DSPE-PEG samples and IL-2/buffer samples. However, fluorescence intensity of IL-2/DSPE-PEG 5000 samples was significantly greater than IL-2/buffer samples. The fluorescence from DSPE-PEG 5000 in buffer alone does not explain this difference. The difference in fluorescence intensity is likely due to the greater amount of aggregate and precipitate present in IL-2/buffer samples. A significant amount of precipitate was noted by visual appearance in the IL-2 /buffer samples after 3 days storage.

Results indicated that IL-2 interacts with DSPE-PEG 5000 (molar ratio W-9:1) at the pI of the protein. This interaction at pH 7 increases the physical stability of IL-2. These results suggested that relatively safe, pegylated phospholipids can be used to stabilize IL-2 in aqueous medium for at least 28 days at 5°C. The underlying mechanism of interaction remains unclear.

Example 8

Effect of PEG Chain Length on Size, CMC and Solubilization Potential of Sterically-stabilized Phospholipid Micelles

According to this example, micelle compositions of the invention were further characterized. Particularly, the physiochemical properties of sterically stabilized micelles prepared with DSPE conjugated to molecular weight 2000, 3000, and 5000 PEG were analyzed.

The critical micelle concentration (CMC) of phospholipids was determined at pH 7.4 and 25°C using a water-insoluble fluorescent probe (1,6-diphenyl-1,3,5-hexatriene).

Micellar size was determined by quasi-elastic light scattering. Solubilization potential of micelles was determined using diazepam as a model hydrophobic drug and RP-HPLC.

As a result, CMC of DSPE-PEG micelles increased from 0.5 to 1.5 μ M range as molecular weight of PEG increased from 2000 to 5000. Mean hydrodynamic diameters (\pm SEM) of micelles were 16.8 \pm 0.3, 20.3 \pm 0.6 and 23.9 \pm 2.1nm for DSPE-PEG 2000, 3000, and 5000, respectively. Furthermore, maximal concentration (\pm SD) of diazepam solubilized in DSPE-PEG 200, 3000, and 5000 was 288.97 \pm 7.51, 224.26 \pm 6.22 and 195.92 \pm 19.73 μ g/ml at a constant concentration of phospholipid (1mM), respectively.

These results indicated that shorter PEG chain length of DSPE-PEG results in smaller micellar size and lower CMC with increased solubilization potential for insoluble drugs. This suggests that DSPE-PEG 2000 micelles are better solubilizers for small hydrophobic molecules, which could be related to an increase in the number of micelles/molar lipid concentration.

Example 9
Characterization of Phospholipid Micelles
by Light Scattering Investigations

According to this example, DSPE conjugated with 1, 2, 3 or 5 kDa PEG in solution, alone or mixed with egg yolk phosphatidylcholine (EYPC) were studied by static (SLS) and dynamic light scattering (DLS).

5 SLS and DLS was used to study micelles in DSPE conjugated with PEG of nominal molecular weight 1, 2, 3 or 5 kDa, either alone or with 25mole% EYPC, as a function of total phospholipid concentration. The phospholipids were dissolved in methanol and dried as a
10 film. The films were dissolved in 10 mM HEPES buffer, pH 7.4, 0.15 NaCl with agitation. The samples were then flushed with nitrogen, sealed and incubated in the dark at room temperature for 48 hours. Samples were passed through a 0.2 μ filter to eliminate dust.

15 The apparatus was configured to measure SLS and DLS as a function of momentum transfer, Q . Q is related to the scattering angle, 2θ , wavelength, $\lambda=632.8$, and medium index of refraction, n , as,

$$Q = \frac{4\pi n}{\lambda} (\sin\theta)$$

20

λ

Correlation functions are measured using ALV-5000 Multiple Tau Digital Correlator over lag times between 2×10^{-7} and 10s. Multiple angle scattering intensity and correlation functions over a large dynamic range allow

detailed characterization of micelle size, shape and polydispersity.

The Guinier approximations for SLS of globular particles,

$$I(Q) = \Delta M \exp - \frac{1}{3} Q^2 R_g^2,$$

5 and equivalent forms for rods and sheets (Hjelm et al., J. Phys. Chem., B104:197 (2000)), are used to make estimates of the particle radius of gyration, R_g in the domain $R_g Q < 1.3 R_g$ and shape. DLS gives estimates of the diffusion coefficient, D , of
 10 particles in a media of viscosity η , by measurements of the time-dependent correlation function. D can be used to estimate the particle hydrodynamic radius, R_H through the Stokes-Einstein equation,

$$R_H = \frac{kT}{6\pi\eta D}$$

These results indicated that DSPE-PEG 1000 does not form micelles in either simple or mixed surfactant solutions. DSPE-PEG at 2, 3, and 5 KDa formed micelles at 1.1 mM and lower with and without EYPC. With EYPC
 20 the micelles were considerably larger. At higher concentrations DSPE-PEG/EYPC mixtures form an anisotropic phase. The characterization of particular forms met the expectations that when EYPC is incorporated into the simple DSPE-PEG micelles, the particular curvature and

shape will change to give a bigger hydrophobic core and therefore the solubilization potential of phospholipid micelles will improve. The results indicate that the size can be controlled by the addition of a second
5 phospholipid. This shows that the approach may be useful in developing micellar drug delivery systems.

Example 10

VIP Receptors as Molecular Targets of Breast Cancer

According to this example the therapeutic uses
10 of the invention are analyzed. Previously, sterically stabilized liposomes (SSL) were prepared with VIP non-covalently associated on their surface. In this example, the need to conjugate VIP covalently to SSL is studied and the targeting ability of VIP-SSL to n-methyl
15 nitrosourea (MNU)-induced rat breast cancer in vitro is tested.

DSPE-PEG₃₄₀₀-NHS [1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine-*n*-[poly(ethylene glycol)]-*N*-hydroxy succinamide, PEG M_w 3400] and polyethylene glycol (M_w
20 2000) conjugated distearyl phosphatidylethanolamine (DSPE-PEG₂₀₀₀) were obtained from Shearwater Polymers, Inc. (Huntsville, AL). BODIPY-Chol (fluorescent cholesterol) was obtained from Molecular Probes Inc. (Portland, OR). Fluo-VIPTM (Portland, OR). Fluo-VIPTM
25 fluorescein labeled VIP) was purchased from Advanced Bioconcept (Montreal, Quebec, Canada). VIP (human/rat) was synthesized, using solid-phase synthesis by Protein

Research Laboratory at Research Resources Center,
University of Illinois at Chicago. Egg-
phosphatidylcholine (PC) and cholesterol (CH) were
obtained from Sygena (Switzerland). Virgin female
5 Sprague-Dawley rats (~140g body weight) were obtained
from Harlan (Indianapolis, IN).

In conducting research using animals, the
investigators adhered to the Institutional Animal Care
Committee guidelines and to the Guide for the Care and
10 Use of Laboratory Animals of the Institute of Laboratory
Animal Resources, National Research Council.

An activated DSPE-PEG (DSPE-PEG₃₄₀₀-NHS) was
used to conjugate VIP to DSPE-PEG₃₄₀₀. This reaction
takes place between amines and NHS group, which acts as
15 the linking agent. VIP and DSPE-PEG₃₄₀₀-NHS in the molar
ratio of 1:5 (VIP:DSPE-PEG₃₄₀₀-NHS) were dissolved
separately in 0.01 M isotonic HEPES buffer, pH 6.6. DSPE-
PEG₃₄₀₀-NHS solution was added in small increments over
1-2 min to the VIP solution at 4°C and then stopped by
20 adding glycine solution to the reaction mixture to
consume the remaining NHS moieties. The conjugation was
tested using SDS-PAGE and subsequent staining with first
Coomassie Blue R-250 and then silver stain. The VIP
conjugated to DSPE-PEG₃₄₀₀ (DSPE-PEG₃₄₀₀-VIP) was
25 subsequently used to prepare fluorescent VIP-SSL.

Breast cancer was induced in rats with MNU as previously described in G.O. Udeani et al., *Cancer Research*, 57:3424-3428 (1997). Briefly, virgin female Sprague-Dawley rats, 36 days old, weighing ~140g, were
5 anesthetized with ketamine/xylazine (13.3/1.3 mg per 100 g body weight, i.m.). Each animal received a single intravenous injection of MNU (50mg/kg body weight) in acidified saline (pH 5.0), via the tail vein. The rats were weighed weekly. They were palpated every week,
10 starting at 3 weeks post-MNU administration. Palpable mammary tumors were detected within 100-150 days after injection.

For testing the in vitro binding, BODIPY-Chol (a non-exchangeable fluorescent probe) containing
15 liposomes, were prepared with film rehydration-extrusion method, as described in S. Dagar et al., *Pharm. Sci.*, 1:S-294 (1998) and M. Patel et al., *Proc. Int. Symp. Control. Rel. Bioact. Mat.*, 24:913-914 (1997) but incorporated the probe at 1:1500 molar ratio
20 (lipid:probe) in the lipid mixture. Egg phosphatidylcholine (PC), cholesterol (CH), DSPE-PEG₂₀₀₀ and dipalmitoyl phosphatidylglycerol (DPPG) in the molar ratios of PC:DPPG:DSPE-PEG₂₀₀₀:CH of 0.50:0.10:0.03:0.35 were used to form the sterically stabilized liposomes by
25 film rehydration and reconstitution using isotonic, 0.01 M HEPES buffer (pH 6.6). This was followed by extrusion

through polycarbonate filters (100nm) using a Liposofast®
(Avestin Inc., Canada) extruder. The size of final
liposomes was ~140 nm as determined using quasi-elastic
light scattering (NICOMP 370, Particle Sizing Systems,
5 Santa Barbara, CA). DSPE-PEG₃₄₀₀-VIP was inserted into
these fluorescent liposomes by overnight incubation at
4°C to form fluorescent VIP conjugated sterically
stabilized liposomes (VIP-SSL).

The rats were euthanized by exposure to carbon
10 dioxide in a closed chamber. Normal and cancerous breast
tissue were excised, frozen immediately in liquid
nitrogen and stored at -70°C until use. The frozen
breast tissue was cut into 20-mm sections and mounted on
microscopic slides. They were then fixed with 4%
15 formaldehyde and allowed to air-dry for 10 min. Adjacent
5mm thick frozen tissue sections, were stained with
hemotoxylin and eosin to confirm the presence or absence
of cancer in the breast tissue. The presence of VIP-R in
these rat breast cancer tissues was confirmed using a
20 fluorescent VIP, FluoVIP™ as described in S. Dagar et
al., *Breast Cancer Res. Treatment* (2000) *in press*.
Twenty micrometer sections of MNU-induced rat breast
cancer tissues were cut using a cryotome, placed on a
slide, fixed with 4% formalin for 20min., and then air-
25 dried for 10min. The BODIPY-Chol containing VIP-SSL were
added to the sections and incubated for 1h at room

temperature. At the end of the incubation period, the slides were washed with 0.01 M isotonic HEPES buffer, pH 6.6, four times for 60s each. The slides were then observed with a Zeiss Camera (Carl Zeiss Inc., Thornwood, NY) and photographed. All photographs were taken with a 2 min exposure using Kodak Elite Chrome 400 photographic film. The VIP-SSL were compared to SSL without VIP or with non-covalently associated VIP and the difference in number of fluorescent liposomes present on the tissue indicated the difference in attachment of VIP-SSL to MNU-induced rat breast cancer tissues.

The reaction conditions were optimized after systemic variation of pH, reaction time, reaction temperature, molar ration of VIP: DSPE-PEG₃₄₀₀ -NHS and stirring rate. It was found that the conditions of reaction (2h at 4°C, pH 6.6, gentle stirring and 1:5 molar ratio) currently used gave the best results. Therefore, the subsequent experiments were done using these optimized conditions. The stained gel (SDS-PAGE) of the conjugation mixture showed that most of the product is 1:1 conjugate of VIP and DSPE-PEG₃₄₀₀ (DSPE-PEG₃₄₀₀--VIP), and free VIP and 1:2 conjugate of VIP and DSPE-PEG₃₄₀₀ exist at much lesser extent as compared to 1:1 DSPE-PEG₃₄₀₀-VIP conjugate. Furthermore, the fluorescence microphotographs of breast cancer tissues indicated that more VIP-SSL were attached to MNU-induced

rat breast cancer tissue sections while SSL without VIP or with non-covalently associated VIP, showed no significant attachment.

In this experiment VIP was successfully
5 conjugated to DSPE-PEG₃₄₀₀ and incorporated into preformed sterically stabilized liposomes to form a VIP-SSL construct. The results showed the feasibility of this novel construct to actively target to MNU-induced rat breast cancer in vitro.

10 Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

What is claimed is:

1. A method of treating a disease state selected from the group consisting of autism, multiple sclerosis, enuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, Cerebral palsy sleep disorder, feeding disorder, inflammatory condition, immune disorder, and AIDS-associated dementias, comprising the step of administering to an individual suffering from the disease state an amount of a liposome composition effective to alleviate conditions associated with the disease state, said liposome composition prepared by a method comprising the steps of:
 - a) mixing a combination of lipids wherein said combination includes at least one lipid component covalently bonded to a water-soluble polymer;
 - b) forming sterically stabilized liposomes from said combination of lipids;
 - c) obtaining liposomes having an average diameter of less than about 300 nm; and
 - d) incubating liposomes from step (c) with a biologically active amphipathic compound under conditions in which said compound becomes associated with said

liposomes from step (c) in an active conformation, wherein at least one amphipathic compound is a member of the VIP/glucagon/secretin family of peptides including peptide fragments and analogs.

2. The method according to claim 1 wherein said liposome composition comprises unilamellar liposomes.

3. The method according to claim 1 wherein said liposome composition comprise multivesicular liposomes.

4. The method of according to claim 3 wherein said multivesicular liposomes are produced by carrying out the steps of sequentially dehydrating and rehydrating liposomes obtained in step (c) with said biologically active peptide.

5. The method according to any one of claims 1 through 4 wherein said water-soluble polymer is polyethylene glycol (PEG).

6. The method according to claim 1 wherein the amphipathic compound is characterized by having one or more α - or π -helical domains in its biologically active conformation.

7. The method according to claim 6 wherein the amphipathic compound is a member of the vasoactive intestinal peptide (VIP)/growth hormone releasing factor (GRF) family of peptides.

8. The method according to claim 7 wherein the amphipathic compound is a member of the VIP/glucagon/secretin family of peptides, including peptide fragments and analogs thereof.

9. The method according to claim 1 wherein the liposomes obtained in step (c) have an average diameter or less than about 200 nm.

10. The method according to claim 9 wherein the liposomes obtained in step (c) have an average diameter or less than about 100 nm.

11. The method according to any one of claims 1, 8, or 9 wherein the liposomes are obtained in step (c) by extrusion to form liposomes having a selected average diameter.

12. The method according to any one of claims 1, 8, or 9 wherein the liposomes are obtained in step (c) by size selection.

13. The method according to claim 1 wherein the combination of lipids consists of distearoyl-

phosphatidylethanolamine covalently bonded to PEG (PEG-DSPE), phosphatidylcholine (PC), and phosphatidylglycerol (PG) in further combination cholesterol (Chol).

14. The method according to claim 13 wherein the combination of lipids are combined with cholesterol in a PEG-DSPE:PC:PG:Chol molar ratio of 0.5:5:1:3.5.

15. A method of preparing an echogenic liposome diagnostic product comprising a biologically active amphipathic compound in association with a liposome; said compound capable of permitting specific targeting within a recipient; said method comprising the steps of:

- a) mixing a combination of lipids wherein said combination includes at least one lipid component covalently bonded to a water-soluble polymer;
- b) forming and obtaining liposomes from said combination of lipids;
- c) incubating liposomes from step (b) with a biologically active amphipathic compound under conditions in which said compound becomes associated with said liposomes from step (b) in an active conformation; and
- d) forming multilamellar liposome products having an average diameter of less than about 1000 nm.

16. The method of claim 15 wherein the multilamellar liposome products are formed by carrying out a lyophilization step.

17. The method of claim 15 wherein the liposomes obtained in step (b) have an average diameter of less than about 300 nm.

18. The method according to claim 17 wherein the liposomes are obtained in step (b) by extrusion.

19. The method according to claim 15 wherein the multilamellar liposome products have an average diameter of less than about 800 nm.

20. The method according to claim 15 wherein the multilamellar liposome products have an average diameter of less than about 300 nm.

21. The method according to any one of claims 15 through 20 wherein the water soluble polymer is PEG.

22. The method of claim 15 wherein the amphipathic compound in a biologically active conformation is characterized as having one or more α or π helical domains.

23. The method of claim 15 wherein the biologically active amphipathic compound is a member of

the vasoactive intestinal peptide (VIP)/growth hormone releasing factor (GRF) family of peptides.

24. The method of claim 15 wherein the peptide is VIP.

25. An echogenic liposome diagnostic product manufactured by the method according to any one of claims 15 through 24.

26. A diagnostic method comprising the steps of:

preparing a multilamellar liposome product comprising a biologically active amphipathic compound in association with a liposome according to the method of claim 15 through 24;

administering a diagnostically effective amount of said multilamellar liposome product to a target tissue; and

detecting the uptake of the multilamellar liposome product at the target tissue by acoustic reflectivity.

27. The method of claim 26 wherein the target tissue is a tumor.

28. The method of claim 26 wherein the amphipathic compound in a biologically active

conformation is characterized as having one or more α or n helical domains.

29. The method of claim 28 wherein the biologically active amphipathic compound is a member of the vasoactive intestinal peptide (VIP)/growth hormone releasing factor (GRF) family of peptides.

30. The method of claim 29 wherein the peptide is VIP.

31. The method of claim 1 wherein the pathology is selected from the group consisting of Hashimoto's thyroiditis, pernicious anemia, Addison's disease, diabetes, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, dermatomyositis, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Graves disease, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, asthma, allergies, inflammatory neuropathies (Guillain Barré, inflammatory polyneuropathies), vasculitis (Wegener's granulomatosis, polyarteritis nodosa), and rare disorders such as polymyalgia rheumatica, temporal arteritis, Sjogren's syndrome, Bechet's disease, Churg-Strauss syndrome, and Takayasu's arteritis.

1 / 7




FIG. 1

2 / 7




FIG. 2A

3/7




FIG. 2B

4/7




FIG. 3

5/7




FIG. 4

6/7




FIG. 5

7/7




FIG. 6